



**OSTEOPORE LIMITED  
AND ITS CONTROLLED ENTITIES**

**ACN 630 538 957**

**CONSOLIDATED ANNUAL REPORT  
FOR THE YEAR ENDED 31 DECEMBER 2024**

**Osteopore Limited and its Controlled Entities**  
**Consolidated Annual Report**  
**For the year ended 31 December 2024**

**CORPORATE INFORMATION**

**Directors**

Mark Leong  
Lim Yujing (Appointed 24 September 2024)  
Professor Teoh Swee Hin  
Daniel Ow  
Michael Keenan

**Company Secretary**

Jack Rosagro (Appointed on 20 May 2024)  
Kellie Davis (Resigned on 20 May 2024)

**Registered and Principal Office**

Level 5, 191 St. Georges Terrace  
Perth WA 6000

Telephone: +61 2 8072 1400

**Share Register**

Automic  
Level 5, 126 Phillip Street  
Sydney NSW 2000

**Auditor**

Grant Thornton Audit Pty Ltd  
Central Park  
Level 43, 152-158 St Georges Terrace  
Perth WA 6000

**Website**

<https://www.osteopore.com/>

**Osteopore Limited and its Controlled Entities**  
**Consolidated Annual Report**  
**For the year ended 31 December 2024**

<b>CONTENTS</b>	<b>PAGE</b>
Letter from the Chairman	3
Directors' Report	5
Auditor's Independence Declaration	22
Consolidated Statement of Profit or Loss and Other Comprehensive Income	23
Consolidated Statement of Financial Position	24
Consolidated Statement of Changes in Equity	25
Consolidated Statement of Cash Flows	26
Notes to the Consolidated Financial Statements	27
Directors' Declaration	61
Independent Auditor's Report	62
Additional ASX Information	65

## **Osteopore Limited and its Controlled Entities**

### **Letter from the Chairman**

On behalf of the Board, I would like to present the 2024 Annual Report to shareholders.

Osteopore Limited (“Osteopore” or the “Company”) is a Singapore-founded regenerative medicine company and a global leader in 3D-printed biomimetic and bioresorbable implants.

The Company operates in the high-growth regenerative medicine sector, where exciting surgical interventions that harness the body’s regenerative capabilities are being developed and commercialised. As one of the prime movers in this nascent sector, Osteopore is focused on bone and rhinoplasty products, which are supported by significant clinical validation, regulatory approval and geographical presence. To maintain its competitive edge and improve product portfolio, the Company is also developing applications in soft tissue applications such as tendon and ligament, while paying attention to opportunities where its scaffold may be included in cell therapy.

In September 2024, the Company announced the appointment of Dr. Lim Yujing as Executive Director, in addition to his roles as CEO and Chief Technology Officer. His appointment strengthens the Board - under Dr. Lim’s direction as CEO since July 2023, the Company oversaw 7 quarters of consecutive growth and a further 25% year-on-year growth in revenue in 2024 (vs 2023). The Company’s financials continue to show improvement: net losses reduced by 31% in 2024 (vs 2023).

Operating with an improved cost structure, the Company’s revenue capture efficiency has further improved. Osteopore is delighted to achieve record high of \$2,762,782 in annual revenue for 2024, which represents a 25% year-on-year growth. In doing so, Osteopore also surpassed 120,000 implants globally while maintaining safety and efficacy.

The revenue distribution by geography remained largely similar to the previous year, reflecting the stability and consistency of Osteopore’s market presence across various regions. Notably, the top five countries collectively accounted for more than 75% of the Company’s annual total revenue.

Each of the top-five performing countries has now achieved a milestone, contributing at least \$100,000 in revenue, which is an improvement over the previous year. This substantiates the Company’s focus on these key markets and demonstrates the potential for continued growth. The Indian market experienced a substantial growth of 376%, the Philippines grew by 71%, while Australia grew by 51% on the back of a distribution refresh with global MNC Zimmer Biomet (NYSE and SIX: ZBH).

These results demonstrate the ability to execute on plans that enabled the Company to capitalise on opportunities across different geographies and navigate challenges. For instance, while revenue in Korea was impacted by the ongoing doctors’ strike, timely, proactive measures ensured that revenues from other regions compensated for this shortfall. In fact, the Company managed to overcome the shortfall and record another year of continued revenue growth.

The orthopaedic business segment also recorded an encouraging start to its commercial journey in Singapore, with global MNC DiethelmKellerSiberHegner (SIX: DKSH) signing a multi-year exclusive arrangement. Osteopore stands to benefit from market expansion specialist DKSH’s expertise in growing its adoption post approvals in March 2024.

Osteopore seized an opportunity to sufficiently recapitalise by entering into an agreement to issue 4% in redeemable convertible notes (RCNs) with an aggregate nominal value of up to \$20,000,000. The Company believes that this is an arrangement that balances access to capital and shareholder interest given the macroeconomic conditions, transient undervaluation, and the belief that Osteopore’s value will be better appreciated with its commercial performance and strategic innovation pipeline.

**Osteopore Limited and its Controlled Entities**  
**Letter from the Chairman**

In 2025, Osteopore will continue to execute its organic growth strategy and maintain its cost structure efficiency. Apart from organic growth, Osteopore will assess suitable inorganic growth opportunities through merger and acquisition (M&A), licensing, and new business lines that expand its value chain capture.



Yours faithfully  
Mark Leong  
Executive Chairman  
Osteopore Limited

## **Osteopore Limited and its Controlled Entities Directors' Report**

The directors present their report, together with the consolidated financial report for Osteopore Limited ("Osteopore" or the "Company") and its controlled entities ("Group"), for the year ended 31 December 2024.

### **DIRECTORS**

The names and details of the Company's directors in office during the financial year and until the date of this report are set out below. Directors were in office for this entire period unless otherwise stated.

<b>Name</b>	<b>Position</b>	<b>Date Appointed</b>	<b>Date Resigned</b>
Mark Leong	Executive Chairman	28 December 2021	-
Lim Yujing	Executive Director	24 September 2024	-
Daniel Ow	Non-Executive Director	7 October 2021	-
Professor Teoh Swee Hin	Non-Executive Director	24 June 2019	-
Michael Keenan	Non-Executive Director	18 July 2023	-

### **PRINCIPAL ACTIVITIES**

Osteopore Ltd. is a global medical technology company founded in Singapore and listed in Australia that commercialises products designed to enable natural bone healing across multiple therapeutic areas. Osteopore's patented technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material.

Osteopore's patent-protected scaffolds are manufactured using a proprietary manufacturing technique with a polymer that naturally dissolves over time to allow natural and healthy bone tissue, significantly reducing the post-surgery complications commonly associated with permanent bone implants. Our 3D printing technology is unique to Osteopore.

### **SIGNIFICANT CHANGES IN STATE OF AFFAIRS**

On 4 March 2024, the Company announced that the consolidation of capital approved by shareholders at the Company's general meeting on 21 February 2024 has been completed. The shareholders approved the consolidation based on a ratio of 15 to 1, which means that every 15 pre-consolidation securities are consolidated into 1 post-consolidation security.

On 7 May 2024, the Company issued 98,626,144 shares raising \$2,860,160 (before costs) in relation to the renounceable pro-rata 10-for-1 Entitlement Offer for eligible shareholders, at an issue price of \$0.029 per share, with one free-attaching option (exercise price \$0.0387) for every 5 new shares subscribed under the Entitlement Offer.

On 24 December 2024, the Company entered into a subscription agreement to issue 4% redeemable convertible notes (RCNs) with an aggregate nominal value of up to \$20,000,000, after receiving shareholders approval in an EGM convened on 23 December 2024.

Other than the above, there were no further significant changes in the state of affairs of the Group during the year ended 31 December 2024.

### **REVIEW OF OPERATIONS**

This is Osteopore's fifth year operating as an ASX-listed company.

Osteopore continues to execute its strategy on growing revenue and optimising efficiencies while not losing sight of product innovation. This focus has led to a year-on-year revenue growth of 25% to \$2,762,782 along with an improvement in its P&L position where its net loss has reduced by 31% year-on-year.

In 2024, Osteopore obtained new product approval in the orthopaedic business segment for Singapore and Vietnam. The Company refreshed its distribution network by signing up with Zimmer Biomet (NYSE and SIX: ZBH) and DiethelmKellerSiberHegner (SIX: DKSH) for its craniofacial products and orthopaedic products

## **Osteopore Limited and its Controlled Entities Directors' Report**

respectively. Zimmer Biomet is ranked 19<sup>th</sup> in the Top 100 medical device companies globally, while DKSH is a Swiss-based specialist company in market expansion services. Osteopore also secured a distribution arrangement for its craniofacial product line in Brazil.

In the product development pipeline, Osteopore announced the successful progress of innovation projects with the University of Chile, the National Dental Centre Singapore and A\*STAR, the National University Hospital Singapore, and Australia's Princess Alexandra Hospital. Apart from these advances, Osteopore also partnered with SingHealth to establish its first Global Centre of Excellence for customised medical devices.

To maintain its edge on medical innovation, Osteopore entered into collaborations with stem cell companies such as US-based RxCell (iPSC) and NASDAQ-listed CytoMed (MSC). In addition, Osteopore signed an Investment Agreement with US renowned scientists Dr. Brian Kennedy and Dr. Zeng Xianmin to drive regeneration innovation.

Osteopore has implemented measures to improve its cost structure, with product development and laboratory expenses reducing by approximately 28%, and sales, marketing and business development expenses by approximately 33% (Note 5). The improving performance of the Company supports the measures taken by the Company.

### *Likely Developments and Expected Results*

The business outlook continues to remain positive for Osteopore despite lukewarm global macroeconomics and heightened political tension. The exclusive distribution arrangement with Zimmer Biomet has set a solid foundation for increased commercial presence for its craniofacial products particularly in Europe and Australia. With specialist market expansion MNC DKSH as commercial partner in Singapore, Osteopore is also prepared for an uptick in its orthopaedic business. The unique Global Centre of Excellence partnership with SingHealth is also expected to provide additional boost to commercial adoption in Singapore and globally.

Osteopore expects at least one more product approval in 2025, which will provide additional opportunity for meaningful revenue capture.

The Company expects to maintain cost structure efficiency while directing sales and marketing efforts to high growth business segments such as orthopaedic implants and customised implants (both craniofacial and orthopaedic). Periodic review of its distribution network for opportunities to accelerate product commercialisation will remain an ongoing focus in 2025. Apart from organic growth, Osteopore will assess suitable inorganic growth opportunities through merger and acquisition (M&A), licensing, and new business lines that expand its value chain capture.

## **REVIEW OF RESULTS**

The Company's 2024 revenue grew 25% year-on-year, while its 2024 net loss after tax of \$3,352,436 (2023: \$4,871,981) was 31% lower than 2023.

The allocation of sales, marketing, and business development expenses was also reduced by close to 33%. Expenditure on sales and marketing yielded better revenue capture, as the appropriate allocation of resource has empowered the Company to report continued revenue growth through most of 2024,

The Group had a net asset position, as of 31 December 2024, of \$306,220 (2023: \$432,603). Osteopore ends the financial year with a cash balance of \$638,498 (2023: \$1,114,800).

## **ENVIRONMENTAL REGULATION**

The Group is not subject to any significant environmental regulation under Australian Commonwealth or State law. There have been no significant known breaches of the consolidated entity's licence conditions or any environmental regulations to which it is subject.

**Osteopore Limited and its Controlled Entities**  
**Directors' Report**

**Directors' Details**

**Mark Leong**

Experience  
*Fellow of ACCA & Chartered Accountant of the Institute of Singapore Chartered Accountants*

**Executive Chairman (Appointed 28 December 2021)**

Mr Leong is a Fellow of the Association of Chartered Certified Accountants (ACCA), Chartered Accountant of the Institute of Singapore Chartered Accountants (ISCA) and Member of the Singapore Institute of Directors (SID). Mr Leong has considerable corporate, management and directorship experience in a broad range of functions in a diverse range of industries having undertaken several C-suite roles (CEO, COO, & CFO) in several private as well as listed companies.

Interest in Shares, Options & Performance Rights

137,500 fully paid ordinary shares, 2,500 listed options, 25,000 unlisted options, 5,625,000 director performance rights

Other Listed Entity Directorships

*Current*  
Non-Executive Director of MDR Limited (SGX:Y3D)  
Non-Executive Director of HS Optimus Holdings Limited (SGX:504)  
Non-Executive Director of 9R Limited (formerly known as Viking Offshore and Marine Limited)(SGX:1Y1)  
Non-Executive Director of LMIRT Management Ltd (SGX:D5IU)  
Non-Executive Director of CytoMed Therapeutics Limited (NASDAQ: GDTG)

*Previous*  
Non-Executive Director of Catalano Seafood Ltd (ASX:CSF)  
Executive Director of LifeBrandz Ltd (SGX: 1D3)

**Lim Yujing**

Experience  
*B Eng, M Eng, PhD Bioengineering (Singapore)*

**Executive Director (Appointed 24 September 2024)**

Dr Lim has been the Chief Executive Officer (CEO) of Osteopore since 18 July 2023, succeeding his appointment as Chief Technology Officer (CTO) in 2018 and Chief Operating Officer (COO) in 2022.

Dr Lim is a Doctor of Philosophy (PhD), Bioengineering and Biomedical Engineering graduate from Nanyang Technology University Singapore, and a Master of Engineering (Mechanical Engineering) and Tissue Engineering graduate from the National University of Singapore.

Interest in Shares, Options & Performance Rights

157,334 fully paid ordinary shares, 5,250 fully paid ordinary shares (held through nominee), 1,050 listed options, 4,125,000 director performance rights

Other Listed Entity Directorships

Dr Lim has no other current and has had no previous listed entity directorships in the last three years.

**Daniel Ow**

Experience  
*B Com, C.P.A (Aust) Graduate Certificate in Financial Planning (FINSIA)*

**Non-Executive Director (Appointed 7 October 2021)**

Mr. Ow has accumulated more than twenty years of international experience spanning various industries, such as infrastructure, resources, property, and fast-moving consumer goods. Throughout his career, he has undertaken several finance and management positions within prominent multinational corporations and holds certification as a Certified Practising Accountant (CPA).

Presently, Mr. Ow holds the role of Chief Financial Officer at Greenpool Capital, a fully integrated property investment, asset, and development firm.



**Osteopore Limited and its Controlled Entities**  
**Directors' Report**

In addition to his professional endeavors, he has also served as a Trustee Director on the Rio Tinto Staff Superannuation Fund, which has since merged with Equip Super.

Interest in Shares, Options & Performance Rights      625,000 director performance rights

Other Listed Entity Directorships      Mr Ow has no other current and has had no previous listed entity directorships in the last three years.

**Professor Teoh Swee Hin**  
 Experience  
*B Eng (1<sup>st</sup> Hons), PhD*  
*Materials Engineering*  
*(Singapore)*

**Non-Executive Director (Appointed 24 June 2019)**

Prof. Teoh is currently the Founding Director and Distinguished Yule Chair Professor, Center for Advanced Medical Engineering (CAME) at the College of Materials Science and Engineering, Hunan University, China. He is Emeritus Professor at School of Chemical and Biomedical Engineering (SCBE) and held joint appointment with the Lee Kong Chian School of Medicine (LKC Med) at Nanyang Technological University (NTU). His contribution is in the development and clinical translation of 3D bioresorbable scaffolds. Majoring in Materials Engineering (B. Eng - 1st Class Hon and PhD, Monash University), his research journey focused on translating the materials research to biomedical benefits. He is a Fellow of the Academy of Engineers Singapore and Chief Engineer at Skin Research Institute of Singapore. His research focused on the study of mechanisms that promote cells proliferation and differentiation as a result of mechano-induction through load bearing scaffolds for tissue regeneration and remodelling.

Prof. Teoh's pioneering work on 3D printed scaffold led to him receiving the prestigious "Golden Innovation Award" at the Far East Economic Review, and the Institute of Engineers "Prestigious Engineering Achievement Award" in 2004. His group was ranked 1st in bone tissue engineering scaffolds in World Web of Science 2010. He was honoured with the Special Award for "Scientific Life-Time Achievement in Bone Tissue Engineering" at Bone-Tec 2015, Stuttgart. As a part of SG50 celebrations, he was featured as one of Singapore's profiled scientists in the book titled "Singapore's Scientific Pioneers".

Presently, he focuses on regenerative medicine research from tissue engineering bone and skin to biomimetic bioreactors to fish collagen, decellularized organs and others. With more than 37 PhDs, 270 research publications and 22 patents and technical disclosures, he is a forerunner and excellent educator in bioengineering and research scientist in translational regenerative medicine.

Interest in Shares, Options & Performance Rights      1,179,089 fully paid ordinary shares, 118,838 listed options, 116,979 unlisted options, 625,000 director performance rights

Other Listed Entity Directorships      Prof. Teoh has no other current and has had no previous listed entity directorships in the last three years.

## Osteopore Limited and its Controlled Entities Directors' Report

### Michael Keenan

#### Experience

### Non-Executive Director (Appointed 18 July 2023)

Mr. Keenan is a former Australian Government Cabinet Minister and brings invaluable expertise in public policy and corporate governance. He served as a Federal Member of Parliament from 2004 to 2019, holding senior ministry positions in the Abbott, Turnbull, and Morrison Governments between 2013 to 2019. His ministerial portfolios included Human Services, where he provided direction and oversight of Medicare, as well as Justice, Counter-Terrorism, and Digital Transformation. Notably, Mr. Keenan also serves on the Board of U Group and Co, as well as the Australian Strategic Policy Institute.

#### Interest in Shares, Options & Performance Rights

625,000 director performance rights

#### Other Listed Entity Directorships

Mr Keenan has no other current and has had no previous listed entity directorships in the last three years.

### Company Secretary

Appointed on 20 May 2024, Mr Jack Rosagro is an experienced Company Secretary and Corporate Governance Advisor to a portfolio of companies including ASX listed and Unlisted Public companies in a range of industries including Software, Biotechnology, and Mineral Exploration. Jack is a Fellow member of the Governance Institute of Australia.

### Meetings of Directors

The number of meetings of the company's Board of Directors ('the Board') and of each Board committee held during the financial year ended 31 December 2024 and the number of meetings attended by each director were:

	Board Meeting		Audit & Compliance Committee Meetings*	
	Eligible to Attend	Attended	Eligible to Attend	Attended
Mark Leong	13	13	-	-
Lim Yujing	3	3	-	-
Daniel Ow	13	12	-	-
Prof. Teoh Swee Hin	13	12	-	-
Michael Keenan	13	12	-	-

\* these are conducted by the Board as a whole, as part of board meetings.

### Matters Subsequent to The End of The Financial Year

#### Convertible Note Agreement

On 24 December 2024, the Company entered into an subscription agreement to issue 4% redeemable convertible notes with an aggregate nominal value of up to \$20,000,000 comprising of 4 equal tranches of nominal value of \$5,000,000 each. Each tranche comprising 20 equal sub-tranches of \$250,000 each. The face value of the convertible notes when issued is \$50,000 each.

The interest amount is equivalent to 100% of the nominal value of the convertible notes at the rate of 4.0% per annum. The interest is payable in cash quarterly in arrears.

## **Osteopore Limited and its Controlled Entities**

### **Directors' Report**

The maturity date of the notes is 36 months from the closing date of the first tranche. A Noteholder may at any time up to 7 calendar days prior to the maturity date exercise its right to convert all outstanding notes into shares. The convertible notes which are not redeemed or purchased, converted or cancelled by the Company on or before the maturity date shall be converted by the Company on the maturity date.

If an issue of shares would result in the voting power in the Company of the noteholder or any other person exceeding 19.99%, the noteholder must make reasonable efforts for the issue to not have that result, and the Company must not issue the relevant shares. To the extent that the convertible notes cannot be converted in to shares (as it would breach the Corporations Act, Foreign Acquisitions and Takeovers Act 1975 or the ASX Listing Rules) or there could be a breach of the minimum free float requirement if the shares are issued, the Company must on notice by the Noteholder redeem the Convertible Notes at 108% together with accrued interest.

The conversion price shall be 80% of the average of the closing price per share on any five consecutive business days as selected by the noteholder during the 45 business days immediately preceding the relevant Conversion Date on which shares were traded on the ASX.

The Company may purchase the outstanding convertible notes at 115% of its principal amount, or such other amount as may be agreed, provided that all outstanding costs, fees and Interest payable under the subscription agreement and the terms and conditions are paid and settled by the Company.

#### Notes issuance

On 14 February 2025, the Company issued 4% redeemable convertible notes with an aggregate nominal value \$2,000,000 in accordance with the subscription agreement as announced on 24 December 2024. In conjunction with this, it is agreed that a portion of the funds raised from the subscription of the Notes will be used to offset the repayment of the total outstanding amount under the bridging loan agreement dated 28 December 2023 and the loan variation deed dated 9 April 2024 between the Company and Advance Opportunities Fund I (Loan). With effect from the issue of the Notes on 14 February 2025, all indebtedness and obligations of the Company in respect of the Loan have been repaid and satisfied in full.

On 7 April 2025, the Company issued 4% redeemable convertible notes with an aggregate nominal value \$1,000,000 in accordance with the subscription agreement.

Apart from the above, the Directors are not aware of any matter or circumstance that has arisen since the end of the financial year that, in their opinion, has significantly affected or may significantly affect in future financial years, the operations of the Group, the results of those operations or the Group's state of affairs.

## **REMUNERATION REPORT (AUDITED)**

The remuneration report details the key management personnel remuneration arrangements for the Company, in accordance with the requirements of the Corporations Act 2001 and the Corporation Regulations 2001. Key management personnel are those persons having authority and responsibility for planning, directing and controlling the activities of the Group, directly or indirectly, including all directors.

The key management personnel of Osteopore Limited for the financial year consists of:

- Mark Leong (Executive Chairman)
- Lim Yujing (Executive Director – appointed 24 September 2024 / Chief Executive Officer / Chief Technology Officer)
- Daniel Ow (Non-Executive Director)
- Professor Teoh Swee Hin (Non-Executive Director)
- Michael Keenan (Non-Executive Director)

### **Principles used to Determine the Nature and Amount of Remuneration**

Remuneration levels for Directors and senior executives of the Company will be competitively set to attract and retain appropriately qualified and experienced Directors and senior executives. The Board may obtain independent advice on the appropriateness of remuneration packages given trends in comparative companies both locally and internationally and the objectives of the Group's remuneration strategy. No such advice was obtained during the current year.

The remuneration structures explained below are designed to attract suitably qualified candidates, reward the achievement of strategic objectives, and achieve the broader outcome of creation of value for shareholders. The remuneration structures take into account:

- the capability and experience of the Directors and senior executives;
- the Directors and senior executives' ability to control the relevant performance;
- the Group's performance; and
- the amount of incentives within each Directors and senior executive's remuneration.

Remuneration packages include a mix of fixed remuneration and variable remuneration and short and long-term performance-based incentives. Short-term incentives include Osteopore's Employee Securities Incentive Plan. The Company's Employee Securities Incentive Plan allows the Board from time to time, in its absolute discretion, make a written offer to any Eligible Participant (as defined in the Plan) to apply for Securities, upon the terms set out in the Plan and upon such additional terms and conditions as the Board determines. In exercising that discretion, the Board may have regard to the following (without limitation):

- I. The Eligible Participant's length of service with the Group;
- II. The contribution made by the Eligible Participant to the Group;
- III. The potential contribution of the Eligible Participant to the Group; or
- IV. Any other matter the Board considers relevant.

Fixed remuneration consists of base remuneration, as well as employer contributions to superannuation funds where applicable or equivalent. Remuneration levels will be, if necessary, reviewed annually by the Board through a process that considers the overall performance of the Group. If required, external consultants provide analysis and advice to ensure the Directors' and senior executives' remuneration is competitive in the marketplace.

Before a determination is made by the Company in a general meeting, the aggregate sum of the fees payable by the Company to the Non-Executive Directors is a maximum of AU\$500,000 per annum.

## Osteopore Limited and its Controlled Entities Directors' Report

### Service Agreements

Remuneration and other terms of employment for key management personnel are formalised in service agreements. Details of these agreements are as follows:

Mark Leong <i>Executive Chairman</i>	Commenced: 28 December 2021 Term: Indefinite term until terminated Remuneration: Base salary of AU\$150,000 per annum Notice period: The contract may be terminated by either party giving not less than one month written notice
Lim Yujing <i>Executive Director / Chief Executive Officer / Chief Technology Officer</i>	Commenced: 17 November 2014, promoted to Chief Executive Officer with effect from 11 July 2023, appointed Executive Director 24 September 2024 Term: Indefinite term until terminated Remuneration: Base salary of SG\$175,500 per annum (exclusive of CPF) Notice period: The contract may be terminated by either party giving six months written notice

### Details of Remuneration

	Fixed Remuneration		At Risk – STI		At Risk – LTI	
	2024	2023	2024	2023	2024	2023
<i>Directors</i>						
Mark Leong	70%	70%	-	-	30%	30%
Lim Yujing <sup>1</sup>	92%	100%	-	-	8%	-
Daniel Ow	84%	86%	-	-	16%	14%
Prof. Teoh Swee Hin	84%	86%	-	-	16%	14%
Michael Keenan	100%	100%	-	-	-	-

<sup>1</sup> Lim Yujing held the position of Chief Executive Officer until 23 September 2024 and was appointed as Executive Director on 24 September 2024

**Osteopore Limited and its Controlled Entities**  
**Directors' Report**

**Details of Remuneration (Continued)**

Details of the remuneration of key management personnel of the Company are set out in the following tables.

	Short-term benefits			Post-employment benefits	Share-based payments		
	Salary and fees	Cash bonus	Non- monetary	Superannuation or equivalent	Equity-settled shares	Equity-settled options	Total
2024	\$	\$	\$	\$	\$	\$	\$
<i>Directors</i>							
Mark Leong	150,000	-	-	-	77,377	-	227,377
Daniel Ow	36,000	-	-	4,050	7,738	-	47,788
Prof. Teoh Swee Hin	36,000	-	-	4,050	7,738	-	47,788
Michael Keenan	36,000	-	-	4,050	92	-	40,142
Lim Yujing <sup>1</sup>	64,790	-	-	5,567	19,574	-	89,931
<i>Key Management Personnel</i>							
Lim Yujing <sup>1</sup>	134,173	-	-	11,489	-	-	145,662
	456,963	-	-	29,206	112,519	-	598,688

<sup>1</sup>Lim Yujing held the position of Chief Executive Officer until 23 September 2024 and was appointed as Executive Director on 24 September 2024

**Osteopore Limited and its Controlled Entities**  
**Directors' Report**

**Details of Remuneration (Continued)**

	Short-term benefits			Post-employment benefits	Share-based payments		
	Salary and fees	Cash bonus	Non- monetary	Superannuation or equivalent	Equity-settled shares	Equity-settled options	Total
<b>2023</b>	\$	\$	\$	\$	\$	\$	\$
<i>Directors</i>							
Mark Leong	150,000	-	-	-	64,904	-	214,904
Daniel Ow	36,000	-	-	3,870	6,490	-	46,360
Prof. Teoh Swee Hin	36,000	-	-	3,870	6,490	-	46,360
Michael Keenan <sup>1</sup>	16,429	-	-	1,807	-	-	18,236
<i>Key Management Personnel</i>							
Lim Yujing	185,727	-	-	16,519	-	-	202,246
	424,156	-	-	26,066	77,884	-	528,106

<sup>1</sup>Appointed on 18 July 2023

**Osteopore Limited and its Controlled Entities**  
**Directors' Report**

**Overview of Company Performance**

The table below sets out information about the Group's earnings and movements in shareholder wealth for the past three years up to and including the current financial year.

	<b>2024</b>	<b>2023</b>	<b>2022</b>
Net loss after tax (\$)	(3,352,436)	(4,871,981)	(4,195,222)
Share price at year end (\$)¹	0.035	0.645	2.325
Basic loss per share (\$)¹	(0.04)	(0.51)	(0.51)
Total dividends (cents per share)	-	-	-

¹Share price and basic loss per share factors in the effect of 15:1 consolidation of capital as approved by shareholders at the General Meeting held on 21 February 2024.

**There is no relationship between the remuneration policy and the performance of the Group.**

**Share-based Compensation**

*Performance Rights Issued as Remuneration*

The terms and conditions of each grant of performance rights over ordinary shares affecting remuneration of directors and other key management personnel in this financial year or past reporting years are as follows.

<b>2024</b>	<b>Number of Performance Rights Granted¹</b>	<b>Grant Date</b>	<b>% Vested</b>	<b>% Unvested</b>
<i>Directors</i>				
Mark Leong	5,625,000	23 December 2024	-	100
Lim Yujing	4,125,000	23 December 2024	-	100
Daniel Ow	625,000	23 December 2024	-	100
Prof. Teoh Swee Hin	625,000	23 December 2024	-	100
Michael Keenan	625,000	23 December 2024	-	100

*Key Management Personnel*

Lim Yujing	-	-	-	-
------------	---	---	---	---

The terms and milestones for the performance rights are listed below and in Note 20.

The fair value of the director performance rights issued during the prior financial year was estimated at the date of grant using the Monte Carlo valuation methodology and key inputs have been summarised below:

	<b>Tranche A</b>	<b>Tranche B</b>	<b>Tranche C</b>	<b>Tranche D</b>	<b>Tranche E</b>
Grant Date	23 Dec 2024	23 Dec 2024	23 Dec 2024	23 Dec 2024	23 Dec 2024
Expiry Date	23 Dec 2029	23 Dec 2029	23 Dec 2029	23 Dec 2029	23 Dec 2029
Share Price at Grant Date (\$) <sup>1</sup>	0.036	0.036	0.036	0.036	0.036
VWAP Hurdle (\$) <sup>1</sup>	0.085	0.12	0.16	0.20	0.25
Risk-free rate (%)	4.076	4.076	4.076	4.076	4.076
Volatility (%)	70	70	70	70	70
Fair value per Performance Right <sup>1</sup>	0.0344	0.0304	0.0270	0.0242	0.0220

There were no performance rights issued as remuneration for the year ended 31 December 2024.



**Osteopore Limited and its Controlled Entities**  
**Directors' Report**

**Share-based Compensation (Continued)**

*Options Issued as Remuneration*

The terms and conditions of each grant of options over ordinary shares affecting remuneration of directors and other key management personnel in this financial year or past reporting years are as follows.

<b>2024</b>	<b>Number of Options Granted<sup>1</sup></b>	<b>Grant Date</b>	<b>Vesting Date</b>	<b>Expiry Date</b>	<b>Exercise Price (\$)</b>	<b>Fair Value per Option (\$)</b>
<i>Directors</i>						
Mark Leong	-	-	-	-	-	-
Daniel Ow	-	-	-	-	-	-
Prof. Teoh Swee Hin	-	-	-	-	-	-
Michael Keenan	-	-	-	-	-	-
<i>Key Management Personnel</i>						
Lim Yujing	-	-	-	-	-	-

<sup>1</sup>The only options granted during the year were free-attaching options in capacity as equity participants in the non-renounceable entitlement offer and did not relate to remuneration.

There were no options granted to key management personnel in the 2024 financial year.

Options granted carry no dividend or voting rights. All options were granted over unissued fully paid ordinary shares in the company. Options vest based on the provision of service over the vesting period whereby the executive becomes beneficially entitled to the option on vesting date. Options are exercisable by the holder as from the vesting date. There has not been any alteration to the terms or conditions of the grant since the grant date. There are no amounts paid or payable by the recipient in relation to the granting of such options other than on their potential exercise.

Values of options over ordinary shares granted, exercised and lapsed for directors and other key management personnel as part of compensation are set out below:

	<b>Value of options Granted/vested during the period \$</b>	<b>Value of options exercised during the period \$</b>	<b>Value of options lapsed during the period \$</b>	<b>Remuneration consisting of options for the period %</b>
<i>Directors</i>				
Mark Leong	-	-	-	-
Daniel Ow	-	-	-	-
Prof Teoh Swee Hin	-	-	-	-
Michael Keenan	-	-	-	-
<i>Key Management Personnel</i>				
Lim Yujing	-	-	-	-

**Osteopore Limited and its Controlled Entities**  
**Directors' Report**

**Additional Disclosures Relating to Key Management Personnel**

*Shareholding*

The number of shares in the Company held during the financial years ended 31 December 2024 and 2023 by each director and other members of key management personnel of the Company, including their personally related parties, is set out below:

	<b>Balance at the start of the year</b>	<b>Received as part of remuneration</b>	<b>Additions</b>	<b>Disposals / Other</b>	<b>Balance at the end of the year</b>
<b>2024</b>					
<i>Directors</i>					
Mark Leong	12,500	-	125,000	-	137,500
Lim Yujing <sup>1</sup>	162,584	-	-	-	162,584
Daniel Ow	-	-	-	-	-
Prof. Teoh Swee Hin	594,192	-	584,897	-	1,179,089
Michael Keenan	-	-	-	-	-
	<b>769,276</b>	<b>-</b>	<b>709,897</b>	<b>-</b>	<b>1,479,173</b>

<sup>1</sup>Lim Yujing held the position of Chief Executive Officer until 23 September 2024 and was appointed as Executive Director on 24 September 2024

	<b>Balance at the start of the year</b>	<b>Received as part of remuneration</b>	<b>Additions</b>	<b>Disposals / Other<sup>1</sup></b>	<b>Balance at the end of the year</b>
<b>2023</b>					
<i>Directors</i>					
Mark Leong	150,000	-	37,500	(175,000)	12,500
Daniel Ow	-	-	-	-	-
Prof. Teoh Swee Hin	7,130,309	-	1,782,577	(8,318,694)	594,192
Michael Keenan	-	-	-	-	-
 <i>Key Management Personnel</i>					
Lim Yujing	2,438,750	-	-	(2,276,166)	162,584
	<b>9,719,059</b>	<b>-</b>	<b>1,820,077</b>	<b>(10,769,860)</b>	<b>769,276</b>

<sup>1</sup>Effect of 15:1 consolidation of capital as approved by shareholders at the General Meeting held on 21 February 2024.

**Osteopore Limited and its Controlled Entities**  
**Directors' Report**

**Additional Disclosures Relating to Key Management Personnel (Continued)**

*Option holding*

The number of options over ordinary shares in the company held during the financial years ended 31 December 2024 and 2023 by each director and other members of key management personnel of the Company, including their personally related parties, is set out below:

<b>2024</b>	<b>Balance at the start of the year</b>	<b>Granted<sup>2</sup></b>	<b>Exercised</b>	<b>Vested</b>	<b>Expired / Forfeited / Other</b>	<b>Balance at the end of the year</b>
<i>Directors</i>						
Mark Leong	2,500	25,000	-	-	-	27,500
Lim Yujing <sup>1</sup>	1,050	-	-	-	-	1,050
Daniel Ow	-	-	-	-	-	-
Prof. Teoh Swee Hin	118,838	116,979	-	-	-	235,817
Michael Keenan	-	-	-	-	-	-
<i>Key Management Personnel</i>						
Lim Yujing	-	-	-	-	-	-
	<b>122,388</b>	<b>141,979</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>264,367</b>

<sup>1</sup>Lim Yujing held the position of Chief Executive Officer until 23 September 2024 and was appointed as Executive Director on 24 September 2024

<sup>2</sup>Options granted during the year were free-attaching options in capacity as equity participant in the renounceable entitlement offer.

<b>2023</b>	<b>Balance at the start of the year</b>	<b>Granted<sup>1</sup></b>	<b>Exercised</b>	<b>Vested</b>	<b>Expired / Forfeited / Other<sup>2</sup></b>	<b>Balance at the end of the year</b>
<i>Directors</i>						
Mark Leong	-	37,500	-	-	(35,000)	2,500
Daniel Ow	-	-	-	-	-	-
Prof. Teoh Swee Hin	-	1,782,577	-	-	(1,663,739)	118,838
Michael Keenan	-	-	-	-	-	-
<i>Key Management Personnel</i>						
Lim Yujing	-	15,750	-	-	(14,700)	1,050
	<b>-</b>	<b>1,835,827</b>	<b>-</b>	<b>-</b>	<b>(1,713,439)</b>	<b>122,388</b>

<sup>1</sup>Options granted during the year were free-attaching options in capacity as equity participant in the non-renounceable entitlement offer.

<sup>2</sup>Effect of 15:1 consolidation of capital as approved by shareholders at the General Meeting held on 21 February 2024.

**Osteopore Limited and its Controlled Entities**  
**Directors' Report**

**Additional Disclosures Relating to Key Management Personnel (Continued)**

*Performance rights*

The number of performance rights over ordinary shares in the company held during the financial year ended 31 December 2024 by each director and other members of key management personnel of the Company, including their personally related parties, is set out below:

<b>2024</b>	<b>Balance at the start of the year</b>	<b>Granted</b>	<b>Exercised</b>	<b>Vested</b>	<b>Expired / Forfeited / Other<sup>1</sup></b>	<b>Balance at the end of the year</b>
<i>Directors</i>						
Mark Leong	616,668	-	-	-	5,008,332	5,625,000
Lim Yujing	-	4,125,000	-	-	-	4,125,000
Daniel Ow	61,668	-	-	-	563,332	625,000
Prof. Teoh Swee Hin	61,668	-	-	-	563,332	625,000
Michael Keenan	-	625,000	-	-	-	625,000
<i>Key Management Personnel</i>						
Lim Yujing	-	-	-	-	-	-
	<b>740,004</b>	<b>4,750,000</b>	<b>-</b>	<b>-</b>	<b>6,134,996</b>	<b>11,625,000</b>

<sup>1</sup>Replacement of the performance rights approved by shareholders at the General Meeting held on 23 December 2024.

*Other Equity-related Key Management Personnel Transactions*

There have been no other transactions involving equity instruments apart from those described in the tables above relating to shareholdings and options.

**Other Transactions with Key Management Personnel and/or their Related Parties**

There were no other transactions conducted between the Group and Key Management Personnel or their related parties, apart from those disclosed above and below, that were conducted other than in accordance with normal employee, customer or supplier relationships on terms no more favourable than those reasonably expected under arm's length dealings with unrelated persons.

	<b>Consolidated</b>	
	<b>31 Dec 2024</b>	<b>31 Dec 2023</b>
	<b>\$</b>	<b>\$</b>
Mark Leong – Expense reimbursements	34,862	24,371
Lim Yujing – Expense reimbursements	2,147	28,056
	<b>37,009</b>	<b>52,427</b>

**End of Remuneration Report (Audited)**

**Osteopore Limited and its Controlled Entities**  
**Directors' Report**

**Share Options**

At the date of this report, the unissued ordinary shares of the Company under option are as follows.

<b>Number of Options Granted<sup>1</sup></b>	<b>Grant Date</b>	<b>Expiry Date</b>	<b>Exercise Price (\$)¹</b>	<b>Fair Value per Option (\$)¹</b>
12,500	27/06/2021	02/11/2025	\$9.360	\$4.26
6,666,667	24/04/2023	24/04/2026	\$3.375	\$0.39
3,333,334	28/06/2023	24/04/2026	\$3.375	\$0.63

**Share Performance Rights**

At the date of this report, the unissued ordinary shares of the Company under performance rights are as follows.

<b>Number of Performance Rights Granted¹</b>	<b>Details</b>	<b>Grant Date</b>	<b>Expiry Date</b>	<b>Fair Value per Performance Right (\$)¹</b>
80,001	Director – Tranche A	31/03/2023	10/05/2028	\$1.1010
120,000	Director – Tranche B	31/03/2023	10/05/2028	\$1.0635
140,001	Director – Tranche C	31/03/2023	10/05/2028	\$1.0095
180,000	Director – Tranche D	31/03/2023	10/05/2028	\$0.9540
220,002	Director – Tranche E	31/03/2023	10/05/2028	\$0.9075

<sup>1</sup>Effect of 15:1 consolidation of capital as approved by shareholders at the General Meeting held on 21 February 2024.

**Non-Audit Services**

No non-audit services were provided by the entity's auditor, Grant Thornton Audit Pty Ltd during the year ended 31 December 2024.

**Indemnification of Officers and Auditors**

The Group has not otherwise, during or since the financial year, except to the extent permitted by law, indemnified or agreed to indemnify an officer or auditor of the Company or of any related body corporate against a liability incurred as such an officer or auditor.

**Proceedings of Behalf of the Company**

No person has applied to the Court under section 237 of the Corporations Act 2001 for leave to bring proceedings on behalf of the Company, or to intervene in any proceedings to which the Company is a party, for the purpose of taking responsibility on behalf of the Company for all or part of those proceedings.

**Auditor's Independence Declaration**

The auditor's independence declaration as required under Section 307C of the Corporations Act 2001 has been received and immediately follows the Directors' Report.

**Dividends Paid or Recommended**

No dividends were paid or recommended during the year ended 31 December 2024.

**Osteopore Limited and its Controlled Entities**  
**Directors' Report**

**Corporate Governance**

In recognising the need for the highest standards of corporate behaviour and accountability, the Directors support and have adhered to principles of sound corporate governance. The Company continued to follow best practice recommendations as set out by the 4<sup>th</sup> edition of the ASX Corporate Governance Council's Corporate Governance Principles and Recommendations. Where the Company has not followed best practice for any recommendation, explanation is given in the Corporate Governance Statement which is available on the Company's website.

Signed in accordance with a resolution of the Directors.



Mark Leong  
Executive Chairman  
7 April 2025

---

**Grant Thornton Audit Pty Ltd**

Level 43 Central Park  
152-158 St Georges Terrace  
Perth WA 6000  
PO Box 7757  
Cloisters Square  
Perth WA 6850  
T +61 8 9480 2000

## Auditor's Independence Declaration

### To the Directors of Osteopore Limited

In accordance with the requirements of section 307C of the *Corporations Act 2001*, as lead auditor for the audit of Osteopore Limited for the year ended 31 December 2024, I declare that, to the best of my knowledge and belief, there have been:

- a no contraventions of the auditor independence requirements of the *Corporations Act 2001* in relation to the audit; and
- b no contraventions of any applicable code of professional conduct in relation to the audit.

Grant Thornton

GRANT THORNTON AUDIT PTY LTD  
Chartered Accountants



J C Rubelli  
Partner – Audit & Assurance

Perth, 7 April 2025

**[www.grantthornton.com.au](http://www.grantthornton.com.au)**  
**ACN-130 913 594**

---

Grant Thornton Audit Pty Ltd ACN 130 913 594 a subsidiary or related entity of Grant Thornton Australia Limited ABN 41 127 556 389 ACN 127 556 389. 'Grant Thornton' refers to the brand under which the Grant Thornton member firms provide assurance, tax and advisory services to their clients and/or refers to one or more member firms, as the context requires. Grant Thornton Australia Limited is a member firm of Grant Thornton International Ltd (GTIL). GTIL and the member firms are not a worldwide partnership. GTIL and each member firm is a separate legal entity. Services are delivered by the member firms. GTIL does not provide services to clients. GTIL and its member firms are not agents of, and do not obligate one another and are not liable for one another's acts or omissions. In the Australian context only, the use of the term 'Grant Thornton' may refer to Grant Thornton Australia Limited ABN 41 127 556 389 ACN 127 556 389 and its Australian subsidiaries and related entities. Liability limited by a scheme approved under Professional Standards Legislation.

**Osteopore Limited and its Controlled Entities**  
**Consolidated Statement of Profit or Loss and Other Comprehensive Income**  
**For the year ended 31 December 2024**

		<b>Consolidated</b>	
	<b>Note</b>	<b>31 Dec 2024</b>	<b>31 Dec 2023</b>
		<b>\$</b>	<b>\$</b>
Revenue	3	2,762,782	2,217,409
Cost of sales		(467,328)	(581,510)
<b>Gross profit</b>		<b>2,295,454</b>	<b>1,635,899</b>
Other income	4	149,298	190,866
Product development and laboratory expenses	5	(1,137,032)	(1,570,762)
Sales, marketing, and business development expenses	5	(1,475,333)	(2,190,313)
Administrative expenses	5	(2,032,192)	(1,864,843)
Other expenses	5	(531,067)	(475,945)
Share-based payments	20	(176,383)	(538,316)
<b>Operating loss</b>		<b>(2,907,255)</b>	<b>(4,813,414)</b>
Finance costs		(426,016)	(15,046)
<b>Loss before income tax</b>		<b>(3,333,271)</b>	<b>(4,828,460)</b>
Income tax expenses	6	(19,165)	(43,521)
<b>Loss after income tax</b>		<b>(3,352,436)</b>	<b>(4,871,981)</b>
<b>Other comprehensive income</b>			
<i>Exchange differences arising from the translation of foreign subsidiary</i>		43,413	(62,541)
<b>Total comprehensive loss attributable to the owners</b>		<b>(3,309,023)</b>	<b>(4,934,522)</b>
Basic and diluted loss per share (\$)	21	(0.04)	(0.51)

*The above consolidated statement of profit or loss and other comprehensive income should be read in conjunction with the accompanying notes*



**Osteopore Limited and its Controlled Entities**  
**Consolidated Statement of Financial Position**  
**As at 31 December 2024**

		<b>Consolidated</b>	
	<b>Note</b>	<b>31 Dec 2024</b>	<b>31 Dec 2023</b>
		<b>\$</b>	<b>\$</b>
<b>ASSETS</b>			
<b>Current Assets</b>			
Cash and cash equivalents	7	638,498	1,114,800
Trade receivables	8	763,023	543,654
Other assets	9	569,368	340,782
Inventories	10	379,515	278,978
<b>Total Current Assets</b>		<b>2,350,404</b>	<b>2,278,214</b>
<b>Non-Current Assets</b>			
Property, plant and equipment	11	160,908	259,479
Right-of-use asset	12	161,603	25,639
Intangible assets	13	461,862	779,889
<b>Total Non-Current Assets</b>		<b>784,373</b>	<b>1,065,007</b>
<b>TOTAL ASSETS</b>		<b>3,134,777</b>	<b>3,343,221</b>
<b>LIABILITIES</b>			
<b>Current Liabilities</b>			
Trade and other payables	14	1,436,302	1,759,223
Borrowings	15	1,163,316	1,064,215
Provisions	16	61,513	58,080
Lease liabilities	17	57,633	29,100
<b>Total Current Liabilities</b>		<b>2,718,764</b>	<b>2,910,618</b>
<b>Non-Current Liabilities</b>			
Lease liabilities	17	109,793	-
<b>Total Non-Current Liabilities</b>		<b>109,793</b>	<b>-</b>
<b>TOTAL LIABILITIES</b>		<b>2,828,557</b>	<b>2,910,618</b>
<b>NET ASSETS</b>		<b>306,220</b>	<b>432,603</b>
<b>EQUITY</b>			
Issued capital	18	32,600,120	29,529,999
Reserves	19	(14,227,838)	(14,383,770)
Accumulated losses		(18,066,062)	(14,713,626)
<b>TOTAL EQUITY</b>		<b>306,220</b>	<b>432,603</b>

*The above consolidated statement of financial position should be read in conjunction with the accompanying notes*

**Osteopore Limited and its Controlled Entities**  
**Consolidated Statement of Changes in Equity**  
**For the year ended 31 December 2024**

	Issued Capital	Share-Based Payment Reserve	Common Control Reserve	Foreign Currency Translation Reserve	Accumulated Losses	Total Equity
	\$	\$	\$	\$	\$	\$
<b>Balance at 31 December 2022</b>	<b>26,957,056</b>	<b>1,113,860</b>	<b>(14,915,451)</b>	<b>(201,408)</b>	<b>(10,902,191)</b>	<b>2,051,866</b>
Loss after income tax	-	-	-	-	(4,871,981)	(4,871,981)
Other comprehensive loss	-	-	-	(62,541)	-	(62,541)
Total comprehensive loss for the year	-	-	-	(62,541)	(4,871,981)	(4,934,522)
Shares placement (Note 18)	2,688,618	-	-	-	-	2,688,618
Share issue costs (Note 18)	(115,675)	-	-	-	-	(115,675)
Share-based payments (Note 19)	-	538,316	-	-	-	538,316
Performance rights issued (vendor) (Note 19)	-	204,000	-	-	-	204,000
Expired options (Note 19)	-	(1,060,546)	-	-	1,060,546	-
<b>Balance at 31 December 2023</b>	<b>29,529,999</b>	<b>795,630</b>	<b>(14,915,451)</b>	<b>(263,949)</b>	<b>(14,713,626)</b>	<b>432,603</b>
Loss after income tax	-	-	-	-	(3,352,436)	(3,352,436)
Other comprehensive income	-	-	-	43,413	-	43,413
Total comprehensive loss for the year	-	-	-	43,413	(3,352,436)	(3,309,023)
Shares placement (Note 18)	3,115,824	-	-	-	-	3,115,824
Share issue costs (Note 18)	(109,568)	-	-	-	-	(109,568)
Share-based payments (Note 19)	63,865	112,519	-	-	-	176,384
<b>Balance at 31 December 2024</b>	<b>32,600,120</b>	<b>908,149</b>	<b>(14,915,451)</b>	<b>(220,536)</b>	<b>(18,066,062)</b>	<b>306,220</b>

*The above consolidated statement of changes in equity should be read in conjunction with the accompanying notes*

**Osteopore Limited and its Controlled Entities**  
**Consolidated Statement of Cash Flows**  
**For the year ended 31 December 2024**

		<b>Consolidated</b>	
		<b>31 Dec 2024</b>	<b>31 Dec 2023</b>
	<b>Note</b>	<b>\$</b>	<b>\$</b>
<b>Cash flows from operating activities</b>			
Loss before income tax		(3,333,271)	(4,828,460)
<i>Adjustments for</i>			
Amortisation expense	13	354,212	262,630
Depreciation (Property, plant, and equipment)	11	124,787	157,366
Depreciation (Right-of-use asset)	12	52,068	44,403
Finance costs		426,016	15,047
Interest income		(1,595)	(7,510)
Share-based payment expense	20	176,383	538,316
Operating cash flows before changes in working capital		(2,201,399)	(3,818,208)
Changes in trade receivables		(219,369)	(261,121)
Changes in other assets		(228,586)	249,438
Changes in inventories		(100,537)	185
Changes in trade and other payables		(343,109)	119,853
Changes in provisions		3,433	(19,751)
Interest received		1,595	7,510
<b>Net cash used in operating activities</b>		<b>(3,087,972)</b>	<b>(3,722,094)</b>
<b>Cash flows from investing activities</b>			
Purchases of plant and equipment		(14,590)	(7,365)
<b>Net cash used in investing activities</b>		<b>(14,590)</b>	<b>(7,365)</b>
<b>Cash flows from financing activities</b>			
Proceeds from shares placement		2,860,160	2,688,618
Proceeds from exercise of options		255,664	-
Payment of shares issue costs		(109,568)	(169,750)
Proceeds from borrowing		-	1,112,491
Repayment of lease principal		(50,596)	(52,242)
Interest paid		(325,892)	(15,047)
<b>Net cash generated from financing activities</b>		<b>2,629,768</b>	<b>3,564,070</b>
Net decrease in cash and cash equivalents		(472,794)	(165,389)
Cash and cash equivalents at the beginning of the year		1,114,800	1,334,221
Effects of exchange rate changes on cash		(3,508)	(54,032)
<b>Cash and cash equivalents at the end of the year</b>		<b>638,498</b>	<b>1,114,800</b>

*The above consolidated statement of cash flows should be read in conjunction with the accompanying notes*

## **Note 1. Material Accounting Policies**

### **General**

These consolidated financial statements and notes represent those of Osteopore Limited (the "Company") and its controlled entities ("Group"). In accordance with the Corporations Act 2001, these financial statements present the results of the Group only. Supplementary information about the Company is disclosed in Note 28: *Parent Entity Disclosures*. The financial report was authorised for issue by the Board on 7 April 2025.

### **Basis of Preparation**

The financial report is a general-purpose financial report which has been prepared in accordance with Australian Accounting Standards, Australian Accounting Interpretations, other authoritative pronouncements of the Australian Accounting Standards Board ("AASB") and the Corporations Act 2001. Osteopore Limited is a for-profit entity for financial reporting purposes under Australian Accounting Standards. Compliance with the Australian Accounting Standards ensures that the financial statements and notes also comply with International Financial Reporting Standards as issued by the International Accounting Standards Board.

Except for cash flow information, the financial report has been prepared on an accruals basis and is based on historical costs, modified where applicable, by the measurement at fair value of selected financial assets and financial liabilities. Cost is based on the fair values of the consideration given in exchange for assets.

The financial statements have been presented in Australian dollars (AUD), which is the functional currency of the Company. The functional currency of the Company's controlled entities is Singapore Dollars (SGD).

### **Going Concern Assumption**

The financial report has been prepared on the going concern basis, which assumes continuity of normal business activities and the realisation of assets and the settlement of liabilities in the ordinary course of business. The Directors note that the Group has net assets of \$306,220 as of 31 December 2024, incurred a net loss for the year of \$3,352,436 and net operating cash outflow of \$3,087,972 for the year ended 31 December 2024. The Group has cash and cash equivalents as of 31 December 2024 of \$638,498.

The Company's ability to continue as a going concern and to pay their debts as and when they fall due is dependent on the Company generating additional revenues from its operations, managing all costs in line with management's forecasts, continuing to draw down further funds under the Convertible Note Subscription Agreement and, if necessary, raising further capital. Management have prepared a cash flow forecast on this basis which indicates that the Consolidated Entity will have sufficient cash flows to meet minimum operating overheads and committed expenditure requirements for the 12-month period from the date of signing the financial report if they are successful in meeting those forecasts.

The Directors believe the Consolidated Entity and Company will continue as a going concern, after consideration of the following factors:

- The Company entered into a subscription agreement on 24th December 2024 with Advance Opportunities Fund and Advance Opportunities Fund I ("AOF") (the "Subscription Agreement") for provision of redeemable convertible notes amounting in aggregate to a sum of up to \$20,000,000 (the "Notes"). Refer to Note 27 for further details.
- AOF has agreed to the issue of notes from Tranche 1 totalling \$2 million on 14 February 2025 and a further \$1 million on 7 April 2025. Directors expect that AOF will continue to agree to the drawdown of further funds during the forecast period.
- Directors undertake regular review of management accounts and cash flow forecasts, incorporating expected cash inflows from sales and collection of trade receivables;
- There is ongoing close management of both the operating costs and corporate overheads;
- The sales pipeline continues to grow, and the Company is confident of achieving further sales growth;

## **Note 1. Material Accounting Policies (Continued)**

### **Going Concern Assumption (Continued)**

- The Group has the ability to be successful in securing additional funds through further debt or equity issues as and when the need to raise working capital arises.

The financial report has therefore been prepared on a going concern basis. Should the Consolidated Entity and the Company be unable to achieve successful outcomes in relation to each of the matters referred to above, there is a material uncertainty whether the Consolidated Entity and the Company will be able to continue as a going concern and, therefore, whether they will realise their assets and discharge their liabilities in the normal course of business. The financial report does not include adjustments relating to the recoverability and classification of recorded asset amounts, nor to the amounts and classification of liabilities that might be necessary should the Consolidated Entity and the Company not continue as a going concern.

### **Foreign Currency**

#### ***Transactions and Balances***

Foreign currency transactions are translated into functional currency using the exchange rates prevailing at the date of the transaction. Foreign currency monetary items are translated at the year-end exchange rate. Non-monetary items measured at historical cost continue to be carried at the exchange rate at the date of the transaction. Non-monetary items measured at fair value are reported at the exchange rate at the date when fair values were determined.

Exchange differences arising on the translation of monetary items are recognised in the statement of profit and loss and other comprehensive income. Exchange differences arising on the translation of non-monetary items are recognised directly in equity to the extent that the gain or loss is directly recognised in equity; otherwise the exchange difference is recognised in the statement of profit and loss and comprehensive income.

#### ***Foreign Operation***

The financial results and position of foreign controlled entities whose functional currency is different from the presentation currency are translated as follows:

- Assets and liabilities are translated at year-end exchange rates prevailing at that reporting date;
- Income and expenses are translated at average exchange rates for the period; and
- Retained earnings are translated at the exchange rates prevailing at the date of the transaction.

Exchange differences arising on translation of foreign controlled entities are transferred directly to the foreign currency translation reserve in the statement of financial position. These differences are recognised in the statement of profit or loss and other comprehensive income in the period in which the operation is disposed.

### **New or Amended Accounting Standards and Interpretations Adopted**

The Group has adopted all of the new or amended Accounting Standards and Interpretations issued by the Australian Accounting Standards Board that are mandatory for the current reporting period. Accounting pronouncements which have become effective from 1 January 2024 and that have been adopted, do not have a significant impact on the Group's financial results or position.

### **Principles of Consolidation**

Subsidiaries are all those entities over which the Group has control. The Group controls an entity when the Group is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power to direct the activities of the entity. Subsidiaries are fully consolidated from the date on which control is transferred to the Group. They are de-consolidated from the date that control ceases.

## **Note 1. Material Accounting Policies (Continued)**

### **Principles of Consolidation (Continued)**

Intercompany transactions, balances and unrealised gains on transactions between entities in the Group are eliminated. Unrealised losses are also eliminated unless the transaction provides evidence of the impairment of the asset transferred. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted by the Group.

The acquisition of subsidiaries is accounted for using the acquisition method of accounting. A change in ownership interest, without the loss of control, is accounted for as an equity transaction, where the difference between the consideration transferred and the book value of the share of the non-controlling interest acquired is recognised directly in equity attributable to the parent.

Non-controlling interest in the results and equity of subsidiaries are shown separately in the statement of profit or loss and other comprehensive income, statement of financial position and statement of changes in equity of the Group. Losses incurred by the Group are attributed to the non-controlling interest in full, even if that results in a deficit balance.

### **Revenue Recognition**

#### *Sale of Goods*

To determine whether to recognise revenue, the Group follow a 5 step process:

1. Identifying the contract with a customer
2. Identifying the performance obligations
3. Determining the transaction price
4. Allocating the transaction price to the performance obligations
5. Recognising revenue when/as the performance obligation(s) are satisfied.

Revenue from the sale of goods is recognised at the point in time when the customer obtains control of the goods, being when the goods have been shipped to the specific location agreed with the customer. Revenue from consignment sales is recognised when the consignment goods are sold to a third-party customer by the consignee, as the Group retains ownership of the consignment stock until the sale to a third-party is completed.

Following delivery, the customer has full discretion over the disposition of the goods, bears the primary responsibility and risks of obsolescence and loss in relations to the goods, as either the customer has accepted the goods in accordance with the sales contract the acceptance provision have lapsed, or the Group has objective evidence that all criteria for acceptance have been satisfied. A receivable is recognised by the Group when the goods are delivered to the customer as this represents the point in time at which the right to consideration becomes unconditional, as only the passage of time is required before payment is due.

No element of financing is deemed present as the sales are made with a credit term of 30-60 days, which is consistent with market practice. Revenue is the amount of consideration to which the entity expects to be entitled in exchange for transferring promised goods or services. Revenue is shown net of estimated customer returns, rebates and other similar allowances.

#### *Interest*

Interest revenue is recognised as interest accrues using the effective interest method. This is a method of calculating the amortised cost of a financial asset and allocating the interest income over the relevant period using the effective interest rate, which is the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset to the net carrying amount of the financial asset.

#### *Other revenue*

Other revenue is recognised when it is received or when the right to receive payment is established.

## **Note 1. Material Accounting Policies (Continued)**

### **Government Grants**

Government grants are recognised when there is reasonable assurance that the grant will be received, and all attaching conditions will be complied with. Where the grant relates to an asset, the fair value is recognised as deferred capital grant on the statement of financial position and is amortised to profit and loss over the expected useful life of the relevant asset by equal annual instalments.

When the grant relates to operating expenditure, the grant income is recognised on a systematic basis in the profit or loss over the periods necessary to match the related cost which they are intended to compensate.

### **Income Tax**

The income tax expense or benefit for the period is the tax payable on that period's taxable income based on the applicable income tax rate for each jurisdiction, adjusted by the changes in deferred tax assets and liabilities attributable to temporary differences, unused tax losses and the adjustment recognised for prior periods, where applicable.

There are many transactions and calculations undertaken during the ordinary course of business for which the ultimate tax determination is uncertain. The consolidated entity recognises liabilities for anticipated tax audit issues based on the consolidated entity's current understanding of the tax law. Where the final tax outcome of these matters is different from the carrying amounts, such differences will impact the current and deferred tax provisions in the period in which such determination is made.

Deferred tax assets and liabilities are recognised for temporary differences at the tax rates expected to be applied when the assets are recovered or liabilities are settled, based on those tax rates that are enacted or substantively enacted. Deferred tax assets are recognised for deductible temporary differences and unused tax losses only if it is probable that future taxable amounts will be available to utilise those temporary differences and losses.

The carrying amount of recognised and unrecognised deferred tax assets are reviewed at each reporting date. Deferred tax assets recognised are reduced to the extent that it is no longer probable that future taxable profits will be available for the carrying amount to be recovered. Previously unrecognised deferred tax assets are recognised to the extent that it is probable that there are future taxable profits available to recover the asset.

Deferred tax assets and liabilities are offset only where there is a legally enforceable right to offset current tax assets against current tax liabilities and deferred tax assets against deferred tax liabilities; and they relate to the same taxable authority on either the same taxable entity or different taxable entities which intend to settle simultaneously.

#### *Tax consolidation*

Osteopore Limited and its wholly owned subsidiaries have not formed an income tax consolidated group under tax consolidation legislation.

### **Goods and Services Tax ('GST') and Other Similar Taxes**

Revenues, expenses and assets are recognised net of the amount of associated GST, unless the GST incurred is not recoverable from the tax authority. In this case it is recognised as part of the cost of the acquisition of the asset or as part of the expense.

Receivables and payables are stated inclusive of the amount of GST receivable or payable. The net amount of GST recoverable from, or payable to, the tax authority is included in other receivables or other payables in the statement of financial position.

## **Note 1. Material Accounting Policies (Continued)**

### **Goods and Services Tax ('GST') and Other Similar Taxes (Continued)**

Cash flows are presented on a gross basis. The GST components of cash flows arising from investing or financing activities which are recoverable from, or payable to the tax authority, are presented as operating cash flows.

Commitments and contingencies are disclosed net of the amount of GST recoverable from, or payable to, the tax authority.

### **Segment Reporting**

An operating segment is a component of the Group that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same entity), whose operating results are regularly reviewed by the Group's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance and for which discrete financial information is available. This includes start-up operations which are yet to earn revenues. Management will also consider other factors in determining operating segments such as the existence of a line manager and the level of segment information presented to the board of directors. Operating segments have been identified based on the information provided to the chief operating decision makers – being the executive management team.

The group aggregates two or more operating segments when they have similar economic characteristics, and the segments are similar in each of the following respects:

- Nature of the products and services;
- Nature of the production processes;
- Type or class of customer for the products and services;
- Methods used to distribute the products or provide the services; and if applicable
- Nature of the regulatory environment.

Operating segments that meet the quantitative criteria as prescribed by AASB 8 are reported separately. However, an operating segment that does not meet the quantitative criteria is still reported separately where information about the segment would be useful to users of the financial statements. Information about other business activities and operating segments that are below the quantitative criteria are combined and disclosed in a separate category for "all other segments".

### **Current and Non-Current Classification**

Assets and liabilities are presented in the statement of financial position based on current and non-current classification.

An asset is classified as current when: it is either expected to be realised or intended to be sold or consumed in the Group's normal operating cycle; it is held primarily for the purpose of trading; it is expected to be realised within 12 months after the reporting period; or the asset is cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least 12 months after the reporting period. All other assets are classified as non-current.

A liability is classified as current when: it is either expected to be settled in the Group's normal operating cycle; it is held primarily for the purpose of trading; it is due to be settled within 12 months after the reporting period; or there is no unconditional right to defer the settlement of the liability for at least 12 months after the reporting period. All other liabilities are classified as non-current.

Deferred tax assets and liabilities are always classified as non-current.



## **Note 1. Material Accounting Policies (Continued)**

### **Cash and Cash Equivalents**

Cash and cash equivalents include cash on hand, deposits held at call with financial institutions, other short-term, highly liquid investments with original maturities of three months or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value.

### **Inventories**

Inventories are stated at the lower of cost and net realisable value. Cost includes all expenses directly attributable to the manufacturing process as well as suitable portions of related production overheads, based on normal operating capacity. Costs of ordinarily interchangeable items are assigned using the first in, first out cost formula. Net realisable value is the estimated selling price in the ordinary course of business less any applicable selling expenses. When necessary, allowance is provided for damaged, obsolete and slow-moving items to adjust the carrying value of inventories to the lower of cost and net realisable value.

### **Intangible Assets**

Intangible assets acquired as part of a business combination, other than goodwill, are initially measured at their fair value at the date of the acquisition. Intangible assets acquired separately are initially recognised at cost. Indefinite life intangible assets are not amortised and are subsequently measured at cost less any impairment. Finite life intangible assets are subsequently measured at cost less amortisation and any impairment. The gains or losses recognised in profit or loss arising from the derecognition of intangible assets are measured as the difference between net disposal proceeds and the carrying amount of the intangible asset. The method and useful lives of finite life intangible assets are reviewed annually. Changes in the expected pattern of consumption or useful life are accounted for prospectively by changing the amortisation method or period.

### **Property, Plant and Equipment**

Property, plant and equipment is measured on the cost basis less depreciation and impairment losses.

The carrying amount of property, plant and equipment is reviewed annually by directors to ensure it is not in excess of the recoverable amount from these assets. The recoverable amount is assessed on the basis of the expected net cash flows that will be received from the asset's employment and subsequent disposal. The expected net cash flows have been discounted to their present values in determining recoverable amounts. An asset's carrying amount is written down immediately to its recoverable amount if the asset's carrying amount is greater than its estimated recoverable amount.

### *Depreciation*

The depreciable amount of all fixed assets is depreciated over its useful life commencing from the time the asset is held ready for use. Depreciation is computed using the straight-line method to write off the cost of these assets over their estimated useful lives as follows:

- Computer 1 year
- Furniture and fittings 5 years
- Plant and machinery 6 years
- Leasehold improvements 5 years

The assets' residual values and useful lives are reviewed, and adjusted if appropriate, at each reporting date and where adjusted, shall be accounted for as a change in accounting estimate. Where depreciation rates or method are changed, the net written down value of the asset is depreciated from the date of the change in accordance with the new depreciation rate or method.

Gains and losses on disposals are determined by comparing proceeds with the carrying amount. These gains and losses are included in profit or loss.

## **Note 1. Material Accounting Policies (Continued)**

### **Impairment of Non-Financial Assets**

The carrying amounts of the Group's non-financial assets are reviewed at each reporting date to determine whether there is any indication of impairment. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the Group estimate the recoverable amount of the cash-generating unit to which the asset belongs.

Recoverable amount is the higher of fair value less costs of disposal and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset.

If the recoverable amount of an asset (or cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognised immediately in profit or loss.

Where an impairment loss subsequently reverses, the carrying amount of the asset (cash-generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (cash-generating unit) in prior years. A reversal of an impairment loss is recognised immediately in profit or loss.

### *Recognition, initial measurement and derecognition*

Financial assets and financial liabilities are recognised when the Group becomes a party to the contractual provisions of the financial instrument and are measured initially at fair value adjusted by transactions costs, except for those carried at fair value through profit or loss, which are measured initially at fair value. Subsequent measurement of financial assets and financial liabilities are described below.

Financial assets are derecognised when the contractual rights to the cash flows from the financial asset expire, or when the financial asset and all substantial risks and rewards are transferred. A financial liability is derecognised when it is extinguished, discharged, cancelled or expires.

### *Classification and subsequent measurement of financial assets*

Except for those trade receivables that do not contain a significant financing component and are measured at the transaction price in accordance with AASB 15, all financial assets are initially measured at fair value adjusted for transaction costs (where applicable).

### **Financial Instruments**

For the purpose of subsequent measurement, financial assets other than those designated and effective as hedging instruments are classified into the following categories upon initial recognition:

- amortised cost
- fair value through profit or loss (FVPL)
- equity instruments at fair value through other comprehensive income (FVOCI)
- debt instruments at fair value through other comprehensive income (FVOCI)

All income and expenses relating to financial assets that are recognised in profit or loss are presented within finance costs, finance income or other financial items, except for impairment of trade receivables which is presented within other expenses.

## **Note 1. Material Accounting Policies (Continued)**

### **Financial Instruments (Continued)**

Classifications are determined by both:

- The entities business model for managing the financial asset
- The contractual cash flow characteristics of the financial assets

#### *Financial assets at amortised cost*

Financial assets are measured at amortised cost if the assets meet the following conditions (and are not designated as FVPL):

- they are held within a business model whose objective is to hold the financial assets and collect its contractual cash flows
- the contractual terms of the financial assets give rise to cash flows that are solely payments of principal and interest on the principal amount outstanding

After initial recognition, these are measured at amortised cost using the effective interest method. Discounting is omitted where the effect of discounting is immaterial. The Group's cash and cash equivalents, trade and most other receivables fall into this category of financial instruments as well as government bonds.

#### *Financial liabilities*

Financial liabilities are recognised initial at fair value adjusted for transaction costs, except where the instrument is classified as fair value through profit or loss, in which case transaction costs are immediately recognised as expenses in profit or loss.

Financial liabilities designated at FVTPL are subsequently measured at fair value. All other financial liabilities recognised by the Group are subsequently measured at amortised cost.

The Group's financial liabilities include trade and other payables, and convertible notes (refer Note 27).

Convertible notes have embedded derivatives within them. Embedded derivatives are separated from the cost contract and accounted for separately if economic characteristics and risks of the host contract and the embedded derivative are not closely related, a separate instrument with the same terms as the embedded derivative would meet the definition of a derivative, and the combined instrument is not measured at fair value through profit or loss.

#### *Impairment of Financial assets*

AASB 9's impairment requirements use forward-looking information to recognize expected credit losses – the 'expected credit losses (ECL) model'. Instruments within the scope of the new requirements included loans and other debt-type financial assets measured at amortised cost and FVOCI, trade receivables, contract assets recognised and measured under AASB 15 and loan commitments and some financial guarantee contracts (for the issuer) that are not measured at fair value through profit or loss.

The Group considers a broad range of information when assessing credit risk and measuring expected credit losses, including past events, current conditions, reasonable and supportable forecasts that affect the expected collectability of the future cash flows of the instrument.

In applying this forward-looking approach, a distinction is made between:

- financial instruments that have not deteriorated significantly in credit quality since initial recognition or that have low credit risk ('Stage 1') and
- financial instruments that have deteriorated significantly in credit quality since initial recognition and whose credit risk is not low ('Stage 2').

## **Note 1. Material Accounting Policies (Continued)**

### **Financial Instruments (Continued)**

'Stage 3' would cover financial assets that have objective evidence of impairment at the reporting date. '12-month expected credit losses' are recognised for the first category while 'lifetime expected credit losses' are recognised for the second category.

Measurement of the expected credit losses is determined by a probability-weighted estimate of credit losses over the expected life of the financial instrument.

#### *Trade and other receivables*

The Group makes use of a simplified approach in accounting for trade and other receivables and records the loss allowance at the amount equal to the expected lifetime credit losses. In using this practical expedient, the Group uses its historical experience, external indicators and forward-looking information to calculate the expected credit losses using a provision matrix.

The Group's financial liabilities include borrowings, trade payables and other payables.

Financial liabilities are initially measured at fair value, and, where applicable, adjusted for transaction costs unless the Group designated a financial liability at fair value through profit or loss.

Subsequently, financial liabilities are measured at amortised cost using the effective interest method except for derivatives and financial liabilities designated at FVPL, which are carried subsequently at fair value with gains or losses recognised in profit or loss (other than derivative financial instruments that are designated and effective as hedging instruments). The Group derecognises financial liabilities when, and only when, the Group's obligations are discharged, cancelled or they expire. The Group does not hold any financial liabilities classified as fair value through profit or loss measurement category.

All interest-related charges and, if applicable, changes in an instrument's fair value that are reported in profit or loss are included within finance costs or finance income.

### **Leases**

#### ***The Group as a lessee***

For any new contracts, the Group considers whether a contract is, or contains a lease. A lease is defined as 'a contract, or part of a contract, that conveys the right to use an asset (the underlying asset) for a period of time in exchange for consideration'.

To apply this definition the Group assesses whether the contract meets three key evaluations which are whether:

- The contract contains an identified asset, which is either explicitly identified in the contract or implicitly specified by being identified at the time the asset is made available to the Group
- The Group has the right to obtain substantially all of the economic benefits from use of the identified asset throughout the period of use, considering its rights within the defined scope of the contract
- The Group has the right to direct the use of the identified asset throughout the period of use. The Group assess whether it has the right to direct 'how and for what purpose' the asset is used throughout the period of use.

#### *Measurement and recognition of leases as a lessee*

At lease commencement date, the Group recognises a right-of-use asset and a lease liability on the balance sheet. The right-of-use asset is measured at cost, which is made up of the initial measurement of the lease liability, any initial direct costs incurred by the Group, an estimate of any costs to dismantle and remove the

## **Note 1. Material Accounting Policies (Continued)**

### **Leases (Continued)**

asset at the end of the lease, and any lease payments made in advance of the lease commencement date (net of any incentives received).

The Group depreciates the right-of-use assets on a straight-line basis from the lease commencement date to the earlier of the end of the useful life of the right-of-use asset or the end of the lease term. The Group also assesses the right-of-use asset for impairment when such indicators exist. At the commencement date, the Group measures the lease liability at the present value of the lease payments unpaid at that date, discounted using the interest rate implicit in the lease if that rate is readily available or the Group's incremental borrowing rate.

Lease payments included in the measurement of the lease liability are made up of fixed payments (including in substance fixed), variable payments based on an index or rate, amounts expected to be payable under a residual value guarantee and payments arising from options reasonably certain to be exercised.

Subsequent to initial measurement, the liability will be reduced for payments made and finance cost. The finance cost is the amount that produces a constant periodic rate of interest on the remaining balance of the lease liability.

The lease liability is reassessed when there is a change in the lease payments. Changes in lease payments arising from a change in the lease term or a change in the assessment of an option to purchase a leased asset. The revised lease payments are discounted using the Group's incremental borrowing rate at the date of reassessment when the rate implicit in the lease cannot be readily determined. The amount of the remeasurement of the lease liability is reflected as an adjustment to the carrying amount of the right-of-use asset. The exception being when the carrying amount of the right-of-use asset has been reduced to zero then any excess is recognised in profit or loss.

Payments under leases can also change when there is either a change in the amounts expected to be paid under residual value guarantees or when future payments change through an index or a rate used to determine those payments, including changes in market rental rates following a market rent review. The lease liability is remeasured only when the adjustment to lease payments takes effect and the revised contractual payments for the remainder of the lease term are discounted using an unchanged discount rate. Except for where the change in lease payments results from a change in floating interest rates, in which case the discount rate is amended to reflect the change in interest rates.

The remeasurement of the lease liability is dealt with by a reduction in the carrying amount of the right-of-use asset to reflect the full or partial termination of the lease for lease modifications that reduce the scope of the lease. Any gain or loss relating to the partial or full termination of the lease is recognised in profit or loss. The right-of-use asset is adjusted for all other lease modifications.

The Group has elected to account for short-term leases and leases of low-value assets using the practical expedients. Instead of recognising a right-of-use asset and lease liability, the payments in relation to these are recognised as an expense in profit or loss on a straight-line basis over the lease term. On the statement of financial position, right-of-use assets have been included in property, plant and equipment (except those meeting the definition of investment property) and lease liabilities have been included in trade and other payables.

## **Note 1. Material Accounting Policies (Continued)**

### **Trade and Other Payables**

These amounts represent liabilities for goods and services provided to the Group prior to the end of the financial year and which are unpaid. Due to their short-term nature they are measured at amortised cost and are not discounted. The amounts are unsecured and are usually paid within 30 days of recognition.

### **Borrowings**

Loans and borrowings are initially recognised at the fair value of the consideration received, net of transaction costs. They are subsequently measured at amortised cost using the effective interest method.

Where there is an unconditional right to defer settlement of the liability for at least 12 months after the reporting date, the loans or borrowings are classified as non-current.

#### *Borrowing costs*

Borrowing costs include interest, amortisation of discounts or premiums relating to borrowings, amortisation of ancillary costs incurred in connection with arrangement of borrowings and lease finance charges. Borrowing costs are expensed as incurred.

### **Convertible Notes**

Convertible notes (with embedded derivatives), that do not contain an equity component are accounted for as a financial liability through profit or loss with a value equating to the total proceed/face value with no day one gain or loss and subsequently the value will change depending on changes in the share price/redemption event and or accretion to the value of the discount on the note. If the convertible note is converted, the carrying amounts of the derivative and liability components are transferred to share capital as consideration for the shares issued. If the note is redeemed, any difference between the amount paid and the carrying amounts of liability is recognised in the statement of profit or loss.

### **Employee Benefits**

#### *Short-Term Benefits*

Short-term employee benefit obligations, including accumulated compensated absences, are measured on an undiscounted basis and are expensed as the related service is provided. A liability is recognised for the amount expected to be paid under short-term cash bonus if the Group has a present legal or constructive obligation to pay this amount as a result of past service provided by the employee, and the obligation can be estimated reliably.

#### *Defined Contribution plans*

The Group participates in the defined contribution national pension schemes as provided by the laws of the countries in which it has operations. A defined contribution plan is a post-employment benefit plan under which an entity pays fixed contributions into a separate entity and will have no legal or constructive obligation to pay further amounts.

#### *Other Employee Entitlements*

Employee entitlements to annual leave and long service leave are recognised when they accrue to employees. Accruals is made for the estimated liability for unconsumed leave as a result of services rendered by employees up to the end of the reporting period.

## **Note 1. Material Accounting Policies (Continued)**

### **Fair Value Measurement**

When an asset or liability, financial or non-financial, is measured at fair value for recognition or disclosure purposes, the fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date; and assumes that the transaction will take place either: in the principal market; or in the absence of a principal market, in the most advantageous market.

Fair value is measured using the assumptions that market participants would use when pricing the asset or liability, assuming they act in their economic best interests. For non-financial assets, the fair value measurement is based on its highest and best use. Valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, are used, maximising the use of relevant observable inputs and minimising the use of unobservable inputs.

Assets and liabilities measured at fair value are classified, into three levels, using a fair value hierarchy that reflects the significance of the inputs used in making the measurements. Classifications are reviewed at each reporting date and transfers between levels are determined based on a reassessment of the lowest level of input that is significant to the fair value measurement.

For recurring and non-recurring fair value measurements, external valuers may be used when internal expertise is either not available or when the valuation is deemed to be significant. External valuers are selected based on market knowledge and reputation. Where there is a significant change in fair value of an asset or liability from one period to another, an analysis is undertaken, which includes a verification of the major inputs applied in the latest valuation and a comparison, where applicable, with external sources of data.

### **Share-Based Payments**

Equity-settled share-based compensation benefits are provided to employees.

Equity-settled transactions are awards of shares, or options over shares that are provided to employees in exchange for the rendering of services. Cash-settled transactions are awards of cash for the exchange of services, where the amount of cash is determined by reference to the share price.

The cost of equity-settled transactions are measured at fair value on grant date. Fair value is independently determined using either the Monte Carlo, Binomial or Black-Scholes option pricing model that takes into account the exercise price, the term of the option, the impact of dilution, the share price at grant date and expected price volatility of the underlying share, the expected dividend yield and the risk free interest rate for the term of the option, together with non-vesting conditions that do not determine whether the Group receives the services that entitle the employees to receive payment. No account is taken of any other vesting conditions.

The cost of equity-settled transactions are recognised as an expense with a corresponding increase in equity over the vesting period. The cumulative charge to profit or loss is calculated based on the grant date fair value of the award, the best estimate of the number of awards that are likely to vest and the expired portion of the vesting period. The amount recognised in profit or loss for the period is the cumulative amount calculated at each reporting date less amounts already recognised in previous periods.

The cost of cash-settled transactions is initially, and at each reporting date until vested, determined by applying either the Binomial, Black-Scholes or Monte Carlo valuation methodology, taking into consideration the terms and conditions on which the award was granted. The cumulative charge to profit or loss until settlement of the liability is calculated as follows:

**Note 1. Material Accounting Policies (Continued)**

- During the vesting period, the liability at each reporting date is the fair value of the award at that date multiplied by the expired option of the vesting period.
- From the end of the vesting period until settlement of the award, the liability is the full fair value of the liability at the reporting date.

All changes in the liability are recognised in profit or loss. The ultimate cost of cash-settled transactions is the cash paid to settle the liability.

Market conditions are taken into consideration in determining fair value. Therefore, any awards subject to market conditions are considered to vest irrespective of whether or not that market condition has been met, provided all other conditions are satisfied.

If equity-settled awards are modified, as a minimum an expense is recognised as if the modification has not been made. An additional expense is recognised, over the remaining vesting period, for any modification that increases the total fair value of the share-based compensation benefit as at the date of modification.

If the non-vesting condition is within the control of the Group or employee, the failure to satisfy the condition is treated as a cancellation. If the condition is not within the control of the Group or employee and is not satisfied during the vesting period, any remaining expense for the award is recognised over the remaining vesting period, unless the award is forfeited.

If equity-settled awards are cancelled, it is treated as if it has vested on the date of cancellation, and any remaining expense is recognised immediately. If a new replacement award is substituted for the cancelled award, the cancelled and new award is treated as if they were a modification.

**Issued Capital**

Ordinary shares are classified as equity. Issued and paid-up capital is recognised at the fair value of the consideration received by the Group. Any transaction costs arising on the issue of ordinary shares are recognised directly in equity as a reduction of the share proceeds received.

Basic loss per share is determined by dividing the operating profit / (loss) after income tax attributable to members of the Company by the weighted average number of ordinary shares outstanding during the financial year

Diluted loss per share adjusts the amounts used in the determination of basic loss per share by taking into account unpaid amounts on ordinary shares and any reduction in loss per share that will probably arise from the exercise of options outstanding during the financial year.

**Dividends**

Dividends are recognised when declared during the financial year and no longer at the discretion of the company.



## **Note 1. Material Accounting Policies (Continued)**

### **Critical Accounting Judgements, Estimates and Assumptions**

The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the reported amounts in the financial statements. Management continually evaluates its judgements and estimates in relation to assets, liabilities, contingent liabilities, revenue and expenses. Management bases its judgements, estimates and assumptions on historical experience and on other various factors, including expectations of future events, management believes to be reasonable under the circumstances. The resulting accounting judgements and estimates will seldom equal the related actual results. The judgements estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are discussed below.

#### *Share-Based Payments*

The Group measures the cost of equity-settled transactions with employees by reference to the fair value of the equity instruments at the date at which they are granted. The fair value is determined by using either the Binomial, Black-Scholes or Monte Carlo valuation model taking into account the terms and conditions upon which the instruments were granted. The accounting estimates and assumptions relating to equity-settled share-based payments would have no impact on the carrying amounts of assets and liabilities within the next annual reporting period but may impact profit or loss and equity.

#### *Allowance for Expected Credit Losses*

The allowance for expected credit losses assessment requires a degree of estimation and judgement. It is based on the lifetime expected credit loss, grouped based on days overdue, and makes assumptions to allocate an overall expected credit loss rate for each group. These assumptions include recent sales experience, historical collection rates, and forward-looking information that is available. The allowance for expected credit losses, as disclosed in Note 8, is calculated based on the information available at the time of preparation. The actual credit losses in future years may be higher or lower.

**Osteopore Limited and its Controlled Entities**  
**Notes to the Consolidated Financial Statements**  
**For the year ended 31 December 2024**

**Note 2. Controlled Entities**

The consolidated financial statements incorporate the assets, liabilities and results of the following wholly owned subsidiaries in accordance with the accounting policy described in Note 1.

	<b>Country of Incorporation</b>	<b>Principal Activities</b>	<b>Ownership 2024 (%)</b>	<b>Ownership 2023 (%)</b>
Osteopore International Pte Ltd	Singapore	Manufacture and trade medical implants	100	100
Osteopore Medico Pte Ltd	Singapore	Manufacture and trade medical implants	100	100
Osteopore Australasia Pty Ltd	Australia	Manufacture and trade medical implants	100	100
Osteopore (Suzhou) Medical Technology Co., Ltd	China	Sale of Class III medical devices and the provision of technology services, research and development.	100	100
Osteopore Korea Co., Ltd	Korea	Manufacture and trade medical implants	100	100

**Note 3. Revenue**

	<b>Consolidated</b>	
	<b>31 Dec 2024</b>	<b>31 Dec 2023</b>
	<b>\$</b>	<b>\$</b>
Sale of goods	2,762,782	2,217,409

All sale of goods is recognised at a point in time.

The Group's revenue disaggregated by primary geographical markets is as follows:

	<b>Consolidated</b>	
	<b>31 Dec 2024</b>	<b>31 Dec 2023</b>
	<b>\$</b>	<b>\$</b>
Vietnam	1,460,154	1,016,512
Philippines	214,867	140,937
South Korea	193,771	308,378
Singapore	167,240	137,464
India	148,418	31,213
Netherlands	85,842	58,751
Thailand	64,427	45,165
Australia	57,656	38,116
Malaysia	52,849	77,666
Other countries	317,558	363,207
	<b>2,762,782</b>	<b>2,217,409</b>

Refer to concentration of customers within credit risk Note 25.

**Osteopore Limited and its Controlled Entities**  
**Notes to the Consolidated Financial Statements**  
**For the year ended 31 December 2024**

**Note 4. Other Income**

	<b>Consolidated</b>	
	<b>31 Dec 2024</b>	<b>31 Dec 2023</b>
	<b>\$</b>	<b>\$</b>
Bank interest income	1,596	7,510
Government grant	49,090	94,206
Adjustment to expected credit loss provision	27,605	34,413
Overprovision for staff unutilised annual leave	11,611	31,891
Insurance recoveries	35,369	-
Other income	24,027	22,846
	<b>149,298</b>	<b>190,866</b>

**Note 5. Expenses**

	<b>Consolidated</b>	
	<b>31 Dec 2024</b>	<b>31 Dec 2023</b>
	<b>\$</b>	<b>\$</b>
<i>Product development and laboratory expenses mainly comprise of:</i>		
Quality assurance audit expenses	54,314	117,034
Regulatory and testing expenses	912	45,482
Research and development expenses	311,457	444,253
Salaries, contributions to defined contribution plans, and other related costs	532,885	739,419
Others	237,464	224,574
	<b>1,137,032</b>	<b>1,570,762</b>
<i>Sales, marketing and business development expenses mainly comprise of:</i>		
Consultancy services	261,048	283,689
Marketing and promotion expenses	41,650	147,025
Trade show and exhibition expenses	67,792	100,330
Travel costs	35,674	138,356
Salaries, contributions to defined contribution plans, and other related costs	799,884	1,147,868
Others	269,285	373,045
	<b>1,475,333</b>	<b>2,190,313</b>
<i>Administrative expenses mainly comprise of:</i>		
ASX and registry expenses	145,865	131,440
Insurance expenses	196,240	217,464
Legal and professional fees	589,483	376,042
Salaries, contributions to defined contribution plans, and other related costs	495,023	530,174
Utilities	99,432	118,367
Others	506,149	491,356
	<b>2,032,192</b>	<b>1,864,843</b>
<i>Other expenses mainly comprise of:</i>		
Amortisation of intangible assets	354,212	262,630
Depreciation – property, plant and equipment	124,787	157,366
Depreciation – right-of-use asset	52,068	44,403
Others	-	11,546
	<b>531,067</b>	<b>475,945</b>

**Osteopore Limited and its Controlled Entities**  
**Notes to the Consolidated Financial Statements**  
**For the year ended 31 December 2024**

**Note 6. Income Tax Expenses**

	<b>Consolidated</b>	
	<b>31 Dec 2024</b>	<b>31 Dec 2023</b>
	<b>\$</b>	<b>\$</b>
<i>The prima facie tax on loss before income tax is reconciled to the income tax as follows:</i>		
Loss before income tax	(3,333,271)	(4,828,460)
Prima facie tax payable on loss from ordinary activities before income tax at 30% (2023: 30%)	(999,981)	(1,448,538)
Non-assessable non-exempt	166,800	305
Share-based payments	52,915	161,495
Foreign tax rate differential	126,754	374,324
Movement in unrecognised deferred tax assets	634,347	955,935
<b>Income tax expenses</b>	<b>19,165</b>	<b>43,521</b>

*Deferred tax assets have not been recognised in respect of the following items:*

Carry forward tax losses – Australia (at 30%):	1,881,814	1,588,886
Carry forward tax losses – Singapore (at 17%):	2,167,570	1,908,618
Carry forward tax losses – China (at 25%):	938	-
<b>Total</b>	<b>4,050,322</b>	<b>3,497,504</b>

The Group has tax losses arising in entities in Australia and Singapore that are available indefinitely to be offset against the future taxable profits of the Group assuming they meet the same-business test and continuity of ownership test.

The potential deferred tax assets, arising from tax losses (as disclosed above) are not brought to account as management is of the view that there is uncertainty in the realisation of the related tax benefits through future taxable profits. The amount of these benefits is based on the assumption that no adverse change will occur in income tax legislation and the anticipation that the Group will derive sufficient future assessable income to enable the benefit to be realised and comply with the conditions of deductibility imposed by law.

**Note 7. Cash and Cash Equivalents**

	<b>Consolidated</b>	
	<b>31 Dec 2024</b>	<b>31 Dec 2023</b>
	<b>\$</b>	<b>\$</b>
Cash in bank and on hand	632,753	1,109,242
Term Deposit	5,745	5,558
	<b>638,498</b>	<b>1,114,800</b>

**Osteopore Limited and its Controlled Entities**  
**Notes to the Consolidated Financial Statements**  
**For the year ended 31 December 2024**

**Note 7. Cash and Cash Equivalents (Continued)**

The carrying amounts of cash and cash equivalents approximate their fair value and are denominated in the following currencies:

Australia dollar	12,272	13,697
Singapore dollar	127,891	937,502
United States dollar	155,832	33,017
Chinese Yuan	746	882
Korean won	341,757	129,702
	<b>638,498</b>	<b>1,114,800</b>

**Note 8. Trade Receivables**

	<b>Consolidated</b>	
	<b>31 Dec 2024</b>	<b>31 Dec 2023</b>
	<b>\$</b>	<b>\$</b>
Trade receivables	780,291	587,217
Less expected credit losses	(17,268)	(43,563)
	<b>763,023</b>	<b>543,654</b>

Trade receivables are non-interest bearing and generally on 30 days term (2023: 30 days). For allowance for expected credit losses analysis at the end of the reporting period, please refer to Note 25.

	<b>Expected credit loss</b>		<b>Carrying Amount (\$)</b>		<b>Allowance of expected credit losses (\$)</b>	
	<b>rate (%)</b>					
	<b>2024</b>	<b>2023</b>	<b>2024</b>	<b>2023</b>	<b>2024</b>	<b>2023</b>
Current	-	2	336,925	338,226	-	5,075
Past due 1 – 60 days	-	3	63,586	40,023	-	1,186
Past due 60 – 180 days	2	28	151,898	101,235	4,011	17,323
Past due 180 – 360 days	3	84	214,220	102,064	6,427	14,310
Past due over 360 days	50	100	13,662	5,669	6,830	5,669
			<b>780,291</b>	<b>587,217</b>	<b>17,268</b>	<b>43,563</b>

Movements in the allowance for expected credit losses are as follows:

	<b>Consolidated</b>	
	<b>31 Dec 2024</b>	<b>31 Dec 2023</b>
	<b>\$</b>	<b>\$</b>
Opening balance	43,563	82,798
Adjustment to provision	(27,605)	(34,413)
Exchange rate movement	1,310	(4,822)
<b>Closing balance</b>	<b>17,268</b>	<b>43,563</b>

**Osteopore Limited and its Controlled Entities**  
**Notes to the Consolidated Financial Statements**  
**For the year ended 31 December 2024**

**Note 9. Other Assets**

	<b>Consolidated</b>	
	<b>31 Dec 2024</b>	<b>31 Dec 2023</b>
	<b>\$</b>	<b>\$</b>
Deposits	43,766	42,570
Prepayments	219,908	198,854
Other receivables	305,694	99,358
	<b>569,368</b>	<b>340,782</b>

**Note 10. Inventories**

	<b>Consolidated</b>	
	<b>31 Dec 2024</b>	<b>31 Dec 2023</b>
	<b>\$</b>	<b>\$</b>
Raw materials	138,130	109,123
Work in progress	120,564	51,044
Finished goods	120,821	118,811
	<b>379,515</b>	<b>278,978</b>

**Note 11. Property, Plant and Equipment**

	<b>Consolidated</b>				
	<b>Computers</b>	<b>Furniture &amp; Fittings</b>	<b>Plant &amp; Machinery</b>	<b>Leasehold Improvements</b>	<b>Total</b>
	<b>\$</b>	<b>\$</b>	<b>\$</b>	<b>\$</b>	<b>\$</b>
Cost	242,445	126,362	765,686	478,742	1,613,235
Less accumulated depreciation	(240,534)	(120,971)	(633,130)	(457,692)	(1,452,327)
Balance at 31 Dec 2024	<b>1,911</b>	<b>5,391</b>	<b>132,556</b>	<b>21,050</b>	<b>160,908</b>
<i>Cost</i>					
Balance at 31 Dec 2022	217,729	115,838	698,937	439,919	1,472,423
Additions	5,705	168	2,434	4,943	13,250
Exchange rate movement	2,052	1,128	6,799	4,244	14,223
Balance at 31 Dec 2023	<b>225,486</b>	<b>117,134</b>	<b>708,170</b>	<b>449,106</b>	<b>1,499,896</b>
Additions	2,103	1,436	10,338	-	13,877
Exchange rate movement	14,856	7,792	47,178	29,636	99,462
Balance at 31 Dec 2024	<b>242,445</b>	<b>126,362</b>	<b>765,686</b>	<b>478,742</b>	<b>1,613,235</b>
<i>Accumulated Depreciation</i>					
Balance at 31 Dec 2022	206,360	92,137	438,908	336,774	1,074,179
Depreciation	16,754	11,649	82,049	46,914	157,366
Exchange rate movement	1,827	781	3,452	2,812	8,872
Balance at 31 Dec 2023	<b>224,941</b>	<b>104,567</b>	<b>524,409</b>	<b>386,500</b>	<b>1,240,417</b>
Depreciation	827	9,111	71,051	43,798	124,787
Exchange rate movement	14,766	7,293	37,670	27,394	87,123
Balance at 31 Dec 2024	<b>240,534</b>	<b>120,971</b>	<b>633,130</b>	<b>457,692</b>	<b>1,452,327</b>

**Osteopore Limited and its Controlled Entities**  
**Notes to the Consolidated Financial Statements**  
**For the year ended 31 December 2024**

**Note 12. Right-Of-Use Asset**

	<b>Consolidated</b>	
	<b>31 Dec 2024</b>	<b>31 Dec 2023</b>
	<b>\$</b>	<b>\$</b>
Cost	192,490	131,856
Less accumulated depreciation	(30,887)	(106,217)
	<b>161,603</b>	<b>25,639</b>
<i>Cost</i>		
Balance at the beginning of the year	131,856	130,581
Additions	6,899	-
Modification/adjustment	42,887	-
Exchange rate movement	10,848	1,275
Balance at the end of the year	<b>192,490</b>	<b>131,856</b>
<i>Accumulated depreciation</i>		
Balance at the beginning of the year	106,217	61,663
Depreciation	52,068	44,403
Modification/adjustment	(131,001)	-
Exchange rate movement	3,603	151
Balance at the end of the year	<b>30,887</b>	<b>106,217</b>

The right-of-use assets relate to the leases for the office premises in Singapore.

**Note 13. Intangible Assets**

	<b>Consolidated</b>	
	<b>31 Dec 2024</b>	<b>31 Dec 2023</b>
	<b>\$</b>	<b>\$</b>
Cost	1,108,470	1,039,852
Less accumulated depreciation	(646,608)	(259,963)
	<b>461,862</b>	<b>779,889</b>
<i>Cost</i>		
Balance at the beginning of the year	1,039,852	-
Additions	-	1,054,000
Exchange rate movement	68,618	(14,148)
Balance at the end of the year	<b>1,108,470</b>	<b>1,039,852</b>
<i>Accumulated amortisation</i>		
Balance at the beginning of the year	259,963	-
Amortisation expense	354,212	262,630
Exchange rate movement	32,433	(2,667)
Balance at the end of the year	<b>646,608</b>	<b>259,963</b>

**Osteopore Limited and its Controlled Entities**  
**Notes to the Consolidated Financial Statements**  
**For the year ended 31 December 2024**

**Note 14. Trade and Other Payables**

	<b>Consolidated</b>	
	<b>31 Dec 2024</b>	<b>31 Dec 2023</b>
	<b>\$</b>	<b>\$</b>
Trade payables	647,048	785,874
Accruals	163,264	258,850
Income tax payable	1,620	-
Other payables	624,370	714,499
	<b>1,436,302</b>	<b>1,759,223</b>

Trade payables are due to third parties, unsecured, interest-free and repayable according to credit terms of 30 days (2023: 30 days). The carrying amounts of trade payables approximate their fair value and are denominated in the following currencies:

Singapore dollar	329,882	626,525
Australia dollar	298,518	159,349
United States dollar	12,841	-
Chinese yuan	2,145	-
Malaysian ringgit	1,313	-
Thai baht	2,349	-
	<b>647,048</b>	<b>785,874</b>

**Note 15. Borrowings**

	<b>Consolidated</b>	
	<b>31 Dec 2024</b>	<b>31 Dec 2023</b>
	<b>\$</b>	<b>\$</b>
Bridging loan <sup>1</sup>	1,112,491	1,112,491
Prepaid interest	-	(100,124)
Insurance premium funding <sup>2</sup>	50,825	51,848
	<b>1,163,316</b>	<b>1,064,215</b>

<sup>1</sup> On 28 December 2023 the Company entered into a bridging loan agreement of face value S\$1,000,000 to fund its working capital and general corporate purposes. The loan has a term of 90 calendar days from the date of disbursement and can be extended for a maximum period of 2 months. The loan has an upfront interest payable of S\$90,000 and an interest rate of 3% per month for the first 3 months, 4% per month for the fourth month, and 5% per month on the fifth month and thereafter. On 9 April 2024, the Company entered into a variation deed to extend the maturity date to 1 May 2025 and change the interest rate to 3% per month. With effect from the issue of the redeemable convertible notes on 14 February 2025, all indebtedness and obligations of the Company in respect of the bridging loan have been repaid and satisfied in full. Refer to Note 27 for further details.

<sup>2</sup> Insurance premium funding relates to funding on Directors' and Officers' Insurance.

**Note 16. Provisions**

	<b>Consolidated</b>	
	<b>31 Dec 2024</b>	<b>31 Dec 2023</b>
	<b>\$</b>	<b>\$</b>
Annual leave provision	26,208	36,054
Other provisions	35,305	22,026
	<b>61,513</b>	<b>58,080</b>



**Osteopore Limited and its Controlled Entities**  
**Notes to the Consolidated Financial Statements**  
**For the year ended 31 December 2024**

**Note 17. Lease Liabilities**

	<b>Consolidated</b>	
	<b>31 Dec 2024</b>	<b>31 Dec 2023</b>
	<b>\$</b>	<b>\$</b>
Current	57,633	29,100
Non-Current	109,793	-
	<b>167,426</b>	<b>29,100</b>

*Amounts recognised in the statement of profit or loss and other comprehensive income*

Depreciation expense on right-of-use asset (Note 12)	52,068	44,403
Interest expense	5,402	5,971

The Group has leases for the office. The lease liabilities are secured by the related underlying assets. Future minimum lease payments at 31 December were as follows:

	<b>Minimum Lease Payments</b>			
	<b>Within 1 Year</b>	<b>1-5 Years</b>	<b>After 5 Years</b>	<b>Total</b>
<b>2024</b>				
Lease payments	64,635	114,595	-	179,230
Finance charges	(7,002)	(4,802)	-	(11,804)
Net present value	57,633	109,793	-	167,426
<b>2023</b>				
Lease payments	30,165	-	-	30,165
Finance charges	(1,065)	-	-	(1,065)
Net present value	29,100	-	-	29,100

**Note 18. Issued Capital**

	<b>2024</b>		<b>2023</b>	
	<b>No. of Shares</b>	<b>\$</b>	<b>No. of Shares</b>	<b>\$</b>
Fully paid ordinary shares	<b>116,801,137</b>	<b>32,600,120</b>	<b>10,328,689<sup>1</sup></b>	<b>29,529,999</b>

Ordinary shares entitle the holder to participate in dividends and the proceeds on the winding up of the Company in proportion to the number of and amounts paid on the shares held. The fully paid ordinary shares have no par value and the Company does not have a limited amount of authorised capital. On a show of hands, every member present at a meeting in person or by proxy shall have one vote and upon a poll each share shall have one vote. There is no current on-market share buy-back.

**Osteopore Limited and its Controlled Entities**  
**Notes to the Consolidated Financial Statements**  
**For the year ended 31 December 2024**

**Note 18. Issued Capital (Continued)**

*Movements in ordinary share capital*

	<b>No. of Shares</b>	<b>Issue price (\$)</b>	<b>\$</b>
<b>Balance at 31 December 2022</b>	<b>123,568,238</b>		<b>26,957,056</b>
Placement on 3 January 2023 <sup>1</sup>	366,666	0.150	55,000
Placement on 24 April 2023 <sup>2</sup>	20,293,604	0.085	1,724,957
Placement on 28 June 2023 <sup>3</sup>	10,690,122	0.085	908,661
Share issue costs			(115,675)
Effect of 15:1 consolidation <sup>4</sup>	(144,589,941)		
<b>Balance at 31 December 2023</b>	<b>10,328,689<sup>1</sup></b>		<b>29,529,999</b>
Placement on 8 May 2024 <sup>5</sup>	98,626,144	0.0290	2,860,160
Placement on 23 May 2024 <sup>6</sup>	602,524	0.0387	23,318
Placement on 27 May 2024 <sup>6</sup>	4,045,634	0.0387	156,566
Placement on 5 June 2024 <sup>6</sup>	370,075	0.0387	14,322
Placement on 12 June 2024 <sup>6</sup>	379,581	0.0387	14,690
Placement on 19 June 2024 <sup>6</sup>	181,332	0.0387	7,017
Placement on 26 June 2024 <sup>6</sup>	36,032	0.0387	1,394
Placement on 3 July 2024 <sup>6</sup>	5,468	0.0388	212
Placement on 10 July 2024 <sup>6</sup>	344,828	0.0387	13,345
Placement on 17 July 2024 <sup>6</sup>	17,972	0.0387	695
Placement on 31 July 2024 <sup>6</sup>	612,858	0.0387	23,718
Placement on 1 November 2024	10,000	0.0387	387
Issuance of shares on 15 November 2024 <sup>7</sup>	763,246	0.0561	42,795
Issuance of shares on 19 November 2024 <sup>7</sup>	476,754	0.0442	21,070
Share issue costs			(109,568)
<b>Balance at 31 December 2024</b>	<b>116,801,137</b>		<b>32,600,120</b>

<sup>1</sup> On 22 December 2022, the Company announced that it has received binding commitments from sophisticated and existing investors for a total \$1,000,000 placement at \$0.15 per share, with one free attaching option for every one new share subscribed for. As of 31 December 2022, the Company has received capital proceeds in advance totalling \$945,000, subsequently, issuing 6,666,666 new fully paid ordinary shares on 3 January 2023. After the reporting date the residual placement totalling \$55,000 was received.

<sup>2</sup> On 24 April 2023, the Company issued 20,293,604 shares in relation to the non-renounceable pro-rata entitlement offer (Entitlement Offer), which gave eligible shareholders the opportunity to subscribe for one fully paid ordinary share for every four fully paid ordinary shares held on the record date, at an issue price of \$0.085 per new share, with one free-attaching quoted option for every one new share subscribed for.

<sup>3</sup> On 28 June 2023, the Company issued 10,690,122 shares in relation to the shortfall shares from the Entitlement Offer.

<sup>4</sup> Effect of 15:1 consolidation of capital as approved by shareholders at the General Meeting held on 21 February 2024.

<sup>5</sup> On 8 May 2024, the Company issue 98,626,144 shares in relation to the renounceable entitlement offer (Entitlement Offer 2024), which gave eligible shareholders the opportunity to subscribe for ten fully paid ordinary shares for every one fully paid ordinary share held on the record date, at an issue price of \$0.029 per new share, with one free-attaching option for every five new shares subscribed for.

<sup>6</sup> This refers to the exercise of options on the respective dates noted.

<sup>7</sup> This refers to the issuance of shares under Employee Securities Incentive Plan.

**Osteopore Limited and its Controlled Entities**  
**Notes to the Consolidated Financial Statements**  
**For the year ended 31 December 2024**

**Note 19. Reserves**

	<b>Consolidated</b>	
	<b>31 Dec 2024</b>	<b>31 Dec 2023</b>
	<b>\$</b>	<b>\$</b>
Common control reserve	(14,915,451)	(14,915,451)
Share-based payment reserve	908,149	795,630
Foreign currency translation reserve	(220,536)	(263,949)
	<b>(14,227,838)</b>	<b>(14,383,770)</b>

**Common Control Reserve**

In September 2019, the Company acquired 100% of Osteopore International Pte Ltd (OIS). The acquisition has been accounted for with reference to common controlled entities. The Group has adopted the predecessor accounting method to form one enlarged group. The Company has recorded the excess consideration above the net asset of OIS to a common control reserve in September 2019.

**Share-Based Payment Reserve**

The share-based payment reserve arises from the equity-settled compensation plan issued to its director, provided that the director remains in continuous employment with the Company from the date of grant. Equity-settled compensation plan is share of commons stock that vest. The terms and conditions of these awards are established in the employment contract.

	<b>No. of Options &amp; Performance Rights</b>	<b>\$</b>
<b>Balance at 31 December 2022</b>	<b>3,187,500</b>	<b>1,113,860</b>
Issue of vendor's performance rights	-	204,000
Issue of directors' performance rights	11,100,000	77,884
Options issued to lead manager of the share placement (Note 20)	15,000,000	460,432
Granted during the period – free-attaching to shareholders	37,650,392	-
Expired options (Note 20)	(3,000,000)	(1,060,546)
Effect of 15:1 consolidation <sup>1</sup>	(59,675,224)	-
<b>Balance at 31 December 2023</b>	<b>4,262,668</b>	<b>795,630</b>
Granted during the period – free-attaching to shareholders	19,725,273	-
Exercised during the period	(6,606,304)	-
Directors' performance rights	10,884,996	93,556
Grant of shares to a director	-	18,963
<b>Balance at 31 December 2024</b>	<b>28,266,633</b>	<b>908,149</b>

<sup>1</sup>Effect of 15:1 consolidation of capital as approved by shareholders at the General Meeting held on 21 February 2024.

**Note 20. Share-Based Payment Expense**

**Options**

On 8 May 2024, 19,725,273 options exercisable at \$0.0387 expiring on 2 April 2026 were issued to the shareholders of the placement. All options are vested at grant date.

The following table illustrates the number and weighted average exercise price and movements in share options:

**Osteopore Limited and its Controlled Entities**  
**Notes to the Consolidated Financial Statements**  
**For the year ended 31 December 2024**

**Note 20. Share-Based Payment Expense (Continued)**

**Options (Continued)**

	31 December 2024		31 December 2023	
	Number	Weighted average exercise price \$	Number	Weighted average exercise price \$
Outstanding at the beginning of year	3,522,664	3.40	3,187,000	1.17
Expired during the year	-	-	(3,000,000)	1.20
Issued to Lead Managers	-	-	15,000,000	0.23
Free-attaching options	19,725,273	0.04	37,650,392	0.23
Exercised during the year	(6,606,304)	0.04	-	-
Effect of 15:1 consolidation	-	-	(49,315,228)	-
Outstanding at the year end	16,641,633	0.75	3,522,664	3.45 <sup>1</sup>
<b>Exercisable at year end</b>	<b>16,641,633</b>	<b>0.75</b>	<b>3,522,664</b>	<b>3.45<sup>1</sup></b>

<sup>1</sup>Effect of 15:1 consolidation of capital as approved by shareholders at the General Meeting held on 21 February 2024.

The fair value of the options issued was estimated at the date of grant using the Black-Scholes option pricing model below:

Grant Date	Expiry Date	Share Price at Grant Date <sup>1</sup>	Exercise Price <sup>1</sup>	Expected Volatility	Dividend Yield	Risk-Free Interest Rate	Fair Value at Grant Date <sup>1</sup>
27/06/2021	02/11/2025	\$7.050	\$9.360	89%	0%	0.82%	\$4.26
24/04/2023	24/04/2026	\$1.140	\$3.375	90%	0%	3.24%	\$0.39
28/06/2023	24/04/2026	\$1.575	\$3.375	90%	0%	3.24%	\$0.63

Set out below are the options exercisable at the end of the financial year:

Grant Date	Expiry Date	31 December 2024 No. of Options	31 December 2023 No. of Options <sup>1</sup>
27/06/2021	02/11/2025	12,500	12,500
31/03/2023	24/04/2026	444,445	444,445
24/04/2023	24/04/2026	2,019,574	2,019,574
28/06/2023	24/04/2026	1,046,145	1,046,145
08/05/2024	02/04/2026	13,118,969	-
		<b>16,641,633</b>	<b>3,522,664</b>

<sup>1</sup>Effect of 15:1 consolidation of capital as approved by shareholders at the General Meeting held on 21 February 2024.

The following table illustrates the number and movements in share performance rights:

**Director Performance Rights**

On 23 December 2024, shareholders of the Company approved the issuance of up to 11,625,000 new director performance rights which replaced the director performance rights which were issued in the prior financial year. In accordance with AASB 2 Share-based payments, this has been treated as a replacement of the prior performance rights which is accounted for as a modification. The fair value of the director performance rights issued was estimated at the date of grant using the Monte Carlo valuation methodology and key inputs have been summarised below:

**Osteopore Limited and its Controlled Entities**  
**Notes to the Consolidated Financial Statements**  
**For the year ended 31 December 2024**

**Note 20. Share-Based Payment Expense (Continued)**

**Director Performance Rights (Continued)**

	<b>Tranche A</b>	<b>Tranche B</b>	<b>Tranche C</b>	<b>Tranche D</b>	<b>Tranche E</b>
Grant Date	23 Dec 2024	23 Dec 2024	23 Dec 2024	23 Dec 2024	23 Dec 2024
Expiry Date	23 Dec 2029	23 Dec 2029	23 Dec 2029	23 Dec 2029	23 Dec 2029
Share Price at Grant Date (\$)	0.036	0.036	0.036	0.036	0.036
VWAP Hurdle (\$)	0.085	0.12	0.16	0.20	0.25
Risk-free rate (%)	4.076	4.076	4.076	4.076	4.076
Volatility (%)	70	70	70	70	70
Fair value per Performance Right <sup>1</sup>	0.0344	0.0304	0.0270	0.0242	0.0220

For the financial year ended 31 December 2024, a total share-based payment expense of \$93,556 (2023: \$77,884) was recognised through profit and loss in relation to the director performance rights.

Refer below for a summary of all share-based payments expensed through profit and loss for the financial year:

	<b>Consolidated</b>	
	<b>31 Dec 2024</b>	<b>31 Dec 2023</b>
	<b>\$</b>	<b>\$</b>
Options	-	460,432
Performance rights	176,383	77,884
	<b>176,383</b>	<b>538,316</b>

**Note 21. Loss per Share**

The following reflects the income and data used in the calculations of basic and diluted loss per share:

	<b>Consolidated</b>	
	<b>31 Dec 2024</b>	<b>31 Dec 2023</b>
	<b>No. of Shares</b>	<b>No. of Shares</b>
Weighted average number of ordinary shares used in calculating basic and diluted loss per share	78,273,212	9,555,653 <sup>1</sup>
	<b>\$</b>	<b>\$</b>
Loss for the year used in calculating operating basic and diluted loss per share	(3,352,436)	(4,871,981)
	<b>\$</b>	<b>\$</b>
Basic and diluted loss per share <sup>1</sup>	(0.04)	(0.51)

<sup>1</sup>Effect of 15:1 consolidation of capital as approved by shareholders at the General Meeting held on 21 February 2024.

As the Group incurred a loss for the period, the options on issue have an anti-dilutive effect therefore the diluted EPS is equal to the basic EPS. A total of 16,641,633 share options (2023: 3,522,664) which could potentially dilute EPS in the future have been excluded from the diluted EPS calculation because they are anti-dilutive for the current year presented.

**Osteopore Limited and its Controlled Entities**  
**Notes to the Consolidated Financial Statements**  
**For the year ended 31 December 2024**

**Note 22. Auditors' Remuneration**

	<b>Consolidated</b>	
	<b>31 Dec 2024</b>	<b>31 Dec 2023</b>
	<b>\$</b>	<b>\$</b>
<i>Remuneration from Audit and Review of Financial Statements</i>		
Audit and review of financial statements ( <i>Grant Thornton Audit Pty Ltd</i> )	106,443	65,532
<i>Other Services</i>		
None	-	-
	<b>106,443</b>	<b>65,532</b>

**Note 23. Related Parties**

	<b>Consolidated</b>	
	<b>31 Dec 2024</b>	<b>31 Dec 2023</b>
	<b>\$</b>	<b>\$</b>
<i>Key Management Personnel Disclosures</i>		
Short term employee benefits	456,963	424,156
Post-employment benefits	29,206	26,066
Share-based payment expenses	112,519	77,884
	<b>598,688</b>	<b>528,106</b>
<i>Transactions with Key Management Personnel and their Related Parties</i>		
Mark Leong – Expense reimbursements	34,862	24,371
Lim Yujing – Expense reimbursements	2,147	28,056
	<b>37,009</b>	<b>52,427</b>

**Osteopore Limited and its Controlled Entities**  
**Notes to the Consolidated Financial Statements**  
**For the year ended 31 December 2024**

**Note 24. Segment Reporting**

The Company has identified its operating segments based on the internal reports that are used by the Board in assessing performance and in determining the allocation of resources. Given the Company's operations since incorporation, the Board has identified four relevant business segments based on the Group's geographical presence – Singapore, Korea, China and Australia. The following tables are an analysis of the Group's revenue and results by reportable segment for the year ended 31 December 2024 and 2023.

	<b>Singapore</b>	<b>Korea</b>	<b>China</b>	<b>Australia</b>	<b>Elimination</b>	<b>Consolidated</b>
	<b>\$</b>	<b>\$</b>	<b>\$</b>	<b>\$</b>	<b>\$</b>	<b>\$</b>
<b>2024</b>						
External revenue	1,297,987	1,425,903	-	38,892	-	2,762,782
Inter-segment revenue	871,349	-	-	-	(871,349)	-
<b>Gross revenue</b>	<b>2,169,336</b>	<b>1,425,903</b>	<b>-</b>	<b>38,892</b>	<b>(871,349)</b>	<b>2,762,782</b>
Other income	105,726	41,862	(7)	1,717	-	149,298
<b>Total revenue</b>	<b>2,275,062</b>	<b>1,467,765</b>	<b>(7)</b>	<b>40,609</b>	<b>(871,349)</b>	<b>2,912,080</b>
<b>(Loss)/profit for the year</b>	<b>(1,495,016)</b>	<b>198,034</b>	<b>(280)</b>	<b>(2,069,876)</b>	<b>14,702</b>	<b>(3,352,436)</b>
Current assets	1,238,143	981,441	1,472	129,348	-	2,350,404
Non-current assets	784,373	-	-	-	-	784,373
<b>Total assets</b>	<b>2,022,516</b>	<b>981,441</b>	<b>1,472</b>	<b>129,348</b>	<b>-</b>	<b>3,134,777</b>
<b>Total liabilities</b>	<b>(1,213,217)</b>	<b>(53,743)</b>	<b>-</b>	<b>(1,561,597)</b>	<b>-</b>	<b>(2,828,557)</b>
<b>2023</b>						
External revenue	1,140,503	1,076,906	-	-	-	2,217,409
Inter-segment revenue	364,521	-	-	-	(364,521)	-
<b>Gross revenue</b>	<b>1,505,024</b>	<b>1,076,906</b>	<b>-</b>	<b>-</b>	<b>(364,521)</b>	<b>2,217,409</b>
Other income	174,723	7,583	3	8,557	-	190,866
<b>Total revenue</b>	<b>1,679,747</b>	<b>1,084,489</b>	<b>3</b>	<b>8,557</b>	<b>(364,521)</b>	<b>2,408,275</b>
<b>(Loss)/profit for the year</b>	<b>(3,317,494)</b>	<b>305,043</b>	<b>(3,509)</b>	<b>(1,831,640)</b>	<b>(24,381)</b>	<b>(4,871,981)</b>
Current assets	1,678,867	479,055	1,649	118,643	-	2,278,214
Non-current assets	1,065,007	-	-	-	-	1,065,007
<b>Total assets</b>	<b>2,743,874</b>	<b>479,055</b>	<b>1,649</b>	<b>118,643</b>	<b>-</b>	<b>3,343,221</b>
<b>Total liabilities</b>	<b>1,568,644</b>	<b>57,100</b>	<b>-</b>	<b>1,284,874</b>	<b>-</b>	<b>2,910,618</b>

## **Note 25. Financial Instruments**

### **Credit Risk**

The Group's activities expose them to credit risk, liquidity risk and market risk - currency, interest rate and price. The Group's overall risk management strategy seeks to minimise adverse effects from the volatility of financial markets on the Group's financial performance.

The Board of Directors is responsible for setting the objectives and underlying principles of financial risk management for the Company. Management then establishes the detailed policies such as authority levels, oversight responsibilities, risk identification and measurement, and exposure limits, in accordance with the objectives and underlying principles approved by the Board of Directors.

There have been no changes to the Group's exposure to these financial risks or the way it manages the risk, except for its credit risk. Market risk exposures are measured using sensitivity analysis indicated below.

Credit risk refers to the risk that counterparty will default on its contractual obligation, resulting in financial loss to the Group. A default on a financial asset is when the counterparty fails to make contractual payments as per agreed terms. This definition of default is determined by considering the business environment in which entity operates and other macro-economic factors.

### *Risk Management*

The Group has adopted a policy of only dealing with creditworthy counterparties as a means of mitigating the risk of financial loss from defaults. The Group do not require collateral from its customers. The Group's major classes of financial assets are trade and other receivables.

Trade receivables that are neither past due nor impaired are substantial companies with good collection track record with the Group. Trade receivables are subjected to credit risk exposure. The Group has identified significant concentration of credit risks for trade receivables as follows:

	<b>Consolidated</b>	
	<b>31 Dec 2024</b>	<b>31 Dec 2023</b>
	<b>%</b>	<b>%</b>
Largest customer percentage of trade receivables	29	24
Largest customer percentage of customer sales	26	33

### *Impairment of Financial Asset*

The Group has the following financial assets that are subject to insignificant credit losses where the expected credit loss ("ECL") model has been applied using the following approaches below. The Group identified \$17,268 of underperforming or non-performing financial assets during the year (2023: \$43,563).

To measure the expected credit losses, trade receivables were grouped based on shared credit risk characteristics. Receivables are written off when there is no reasonable expectation of recovery, such as a debtor failing to engage in a repayment plan with the Group.

The Group determines the ECL by using a provision matrix, estimated based on historical credit loss experience based on the past due status of the debtors, adjusted as appropriate to reflect current conditions and estimates of future economic conditions. Accordingly, the credit risk profile of these assets is presented based on their past due status in terms of the provision matrix.



**Note 25. Financial Instruments (Continued)**

**Credit Risk (Continued)**

For the purpose of impairment assessment, other receivables are considered to have low credit risk as they are not due for payment at the end of the reporting period and there has been no significant increase in the risk of default on the receivables since initial recognition. Accordingly, the loss allowance is measured at an amount equal to 12-month ECL.

In determining the ECL, the historical default experience and financial position of the counterparties are taken into account, adjusted for factors that are specific to the debtors and general economic conditions of the industry in which the debtors operate, in estimating the probability of default of each of these financial assets occurring within their respective loss assessment time horizon, as well as the loss upon default in each case.

There has been no change in estimation techniques or significant assumptions made during the current reporting period in assessing the loss allowance for other receivables.

**Market Risk**

Market risk is the risk that changes in market price, such as interest rates and foreign exchange rates will affect the Group's income. The objective of market risk management is to manage and control market risk exposures within acceptable parameters, while optimising the return on risk.

*Foreign Currency Risk*

The Group's foreign exchange risk results mainly from cash flows from transactions denominated in foreign currencies. At present, the Group does not have any formal policy for hedging against currency risk. The Group ensures that the net exposure is kept to an acceptable level by buying or selling foreign currencies at spot rates, where necessary, to address short term imbalances between entities.

The carrying amount of the Group's foreign currency denominated financial assets and financial liabilities at the reporting date were as follows:

	<b>2024</b>		<b>2023</b>	
	<b>Assets</b>	<b>Liabilities</b>	<b>Assets</b>	<b>Liabilities</b>
	<b>\$</b>	<b>\$</b>	<b>\$</b>	<b>\$</b>
Singapore dollar	985,628	921,086	1,591,304	1,568,645
Chinese yuan	746	2,145	882	-
United States dollar	469,402	13,822	33,017	-
Korean won	582,647	53,743	431,571	57,100
Swiss franc	8,910	-	-	-
Euros	21,251	-	-	-
Indian rupee	38,872	-	-	-
Malaysian ringgit	-	1,313	-	-
Philippine peso	-	8,639	-	-
Thai baht	-	2,349	-	-
	<b>2,107,456</b>	<b>1,003,097</b>	<b>2,056,774</b>	<b>1,625,745</b>

The Group had net assets denominated in foreign currencies of \$1,104,359 (2023: \$431,029). At 31 December 2024, if the Singapore dollar weakened by 10% against these foreign currencies with all other variables held constant, the Group's loss before tax would have been \$110,436 lower (2023: \$43,103) and equity would have been \$110,436 lower (2023: \$43,103). The percentage change is the expected overall volatility of the significant currencies, which is based on management's assessment of reasonable possible fluctuations taking into consideration movements over the last 6 months each year and the spot rate at each reporting date.

**Osteopore Limited and its Controlled Entities**  
**Notes to the Consolidated Financial Statements**  
**For the year ended 31 December 2024**

**Note 25. Financial Instruments (Continued)**

**Market Risk (Continued)**

The net foreign exchange loss included in other expenses for the year ended 31 December 2024 was \$23,740 (2023: \$11,548).

*Interest Rate Risk*

The Group's exposure to the risks of changes in market interest rates relates primarily to the Group's short-term deposits with a floating interest rate. These financial assets with variable rates expose the Group to cash flow interest rate risk. All other financial assets and liabilities in the form of receivables and payables are non-interest bearing. The Group does not engage in any hedging or derivative transactions to manage interest rate risk. The Group has not entered any hedging activities to cover interest rate risk. Regarding its interest rate risk, the Group does not have a formal policy in place to mitigate such risks.

The following table set out the carrying amount by maturity of the Group's exposure to interest rate risk and the effective weighted average interest rate for each class of these financial instruments.

	<b>Fixed Interest Rate</b>					<b>Total</b>	<b>Weighted Average Interest Rate</b>
	<b>Non-Interest Bearing</b>	<b>&lt; 1 Year</b>	<b>1 – 5 Years</b>	<b>&gt; 5 years</b>	<b>Floating Interest Rate</b>		
<b>2024</b>	<b>\$</b>	<b>\$</b>	<b>\$</b>	<b>\$</b>	<b>\$</b>	<b>\$</b>	
<i>Financial assets</i>							
Cash and cash equivalents	632,753	-	-	-	5,745	638,498	0.04%
<i>Financial liabilities</i>							
Borrowings	-	1,163,316	-	-	-	1,163,316	36.00%
<b>2023</b>							
<i>Financial assets</i>							
Cash and cash equivalents	1,101,104	-	-	-	13,696	1,114,800	0.04%
<i>Financial liabilities</i>							
Borrowings	-	1,164,339	-	-	-	1,164,339	36.00%

**Liquidity Risk**

The Group manages liquidity risk by maintaining sufficient cash reserves and marketable securities and through the continuous monitoring of budgeted and actual cash flows. No liquidity risk has been disclosed for the Group as the Group's financial assets and liabilities are contractually due on demand or within one year, and the undiscounted cash flows approximate the carrying amounts as reported on the statement of financial position.

**Fair Values**

For other assets and liabilities, the net fair value approximates their carrying value. The Group has no financial assets or liabilities that are readily traded on organised markets and has no financial assets where the carrying amount exceeds net fair values at the reporting date.

The aggregate net fair values and carrying amounts of financial assets and financial liabilities are disclosed in the statement of financial position and in the notes to the financial statements.

## **Note 26. Contingent Assets and Liabilities**

The Directors of the Group are not aware of any contingent liabilities which require disclosure in the financial year ended 31 December 2024 (2023: nil).

## **Note 27. Subsequent Events**

### Convertible Note Agreement

On 24 December 2024, the Company entered into an subscription agreement to issue 4% redeemable convertible notes with an aggregate nominal value of up to \$20,000,000 comprising of 4 equal tranches of nominal value of \$5,000,000 each. Each tranche comprising 20 equal sub-tranches of \$250,000 each. The face value of the convertible notes when issued is \$50,000 each.

The interest amount is equivalent to 100% of the nominal value of the convertible notes at the rate of 4.0% per annum. The interest is payable in cash quarterly in arrears.

The maturity date of the notes is 36 months from the closing date of the first tranche. A Noteholder may at any time up to 7 calendar days prior to the maturity date exercise its right to convert all outstanding notes into shares. The convertible notes which are not redeemed or purchased, converted or cancelled by the Company on or before the maturity date shall be converted by the Company on the maturity date.

If an issue of shares would result in the voting power in the Company of the noteholder or any other person exceeding 19.99%, the noteholder must make reasonable efforts for the issue to not have that result, and the Company must not issue the relevant shares. To the extent that the convertible notes cannot be converted in to shares (as it would breach the Corporations Act, Foreign Acquisitions and Takeovers Act 1975 or the ASX Listing Rules) or there could be a breach of the minimum free float requirement if the shares are issued, the Company must on notice by the Noteholder redeem the Convertible Notes at 108% together with accrued interest.

The conversion price shall be 80% of the average of the closing price per share on any five consecutive business days as selected by the noteholder during the 45 business days immediately preceding the relevant Conversion Date on which shares were traded on the ASX.

The Company may purchase the outstanding convertible notes at 115% of its principal amount, or such other amount as may be agreed, provided that all outstanding costs, fees and Interest payable under the subscription agreement and the terms and conditions are paid and settled by the Company.

### Notes issuance

On 14 February 2025, the Company issued 4% redeemable convertible notes with an aggregate nominal value \$2,000,000 in accordance with the subscription agreement as announced on 24 December 2024. In conjunction with this, it is agreed that a portion of the funds raised from the subscription of the Notes will be used to offset the repayment of the total outstanding amount under the bridging loan agreement dated 28 December 2023 and the loan variation deed dated 9 April 2024 between the Company and Advance Opportunities Fund I (Loan). With effect from the issue of the Notes on 14 February 2025, all indebtedness and obligations of the Company in respect of the Loan have been repaid and satisfied in full.

**Osteopore Limited and its Controlled Entities**  
**Notes to the Consolidated Financial Statements**  
**For the year ended 31 December 2024**

**Note 27. Subsequent Events (Continued)**

On 7 April 2025, the Company issued 4% redeemable convertible notes with an aggregate nominal value \$1,000,000 in accordance with the subscription agreement.

Apart from the above, the Directors are not aware of any matter or circumstance that has arisen since the end of the financial year that, in their opinion, has significantly affected or may significantly affect in future financial years, the operations of the Group, the results of those operations or the Group's state of affairs.

**Note 28. Parent Entity Disclosures**

The following information has been extracted from the books and records of the legal parent, being Osteopore Limited and has been prepared in accordance with Accounting Standards.

	<b>Consolidated</b>	
	<b>31 Dec 2024</b>	<b>31 Dec 2023</b>
	<b>\$</b>	<b>\$</b>
<i>Financial Position</i>		
Total current assets	2,577,144	2,427,524
Total non-current assets	-	-
<b>Total assets</b>	<b>2,577,144</b>	<b>2,427,524</b>
Total current liabilities	2,270,925	1,994,922
<b>Total liabilities</b>	<b>2,270,925</b>	<b>1,994,922</b>
<b>Net assets</b>	<b>306,219</b>	<b>432,602</b>
Issued capital	32,600,120	29,529,999
Common control reserve	(14,915,451)	(14,915,451)
Share-based payment reserve	908,150	795,631
Accumulated losses	(18,286,600)	(14,977,577)
<b>Total equity</b>	<b>306,219</b>	<b>432,602</b>
<i>Financial Performance</i>		
Loss for the year	(6,414,496)	(4,934,522)
Other comprehensive income	-	-
<b>Total comprehensive loss</b>	<b>(6,414,496)</b>	<b>(4,934,522)</b>

The Parent Entity has no capital commitments and has not entered into a deed of cross guarantee nor are there any contingent liabilities at the year end.

**Osteopore Limited and its Controlled Entities**  
**Notes to the Consolidated Financial Statements**  
**For the year ended 31 December 2024**

**Consolidated Entity Disclosure Statement**

**Basis of preparation**

The Consolidated Entity Disclosure Statement has been prepared in accordance with the *Corporations Act 2001* and includes information for each entity that was part of the consolidated entity as at the end of the financial year in accordance with *AASB 10 Consolidated Financial Statements*.

Entity name	Entity type	Place formed / Country of incorporation	Ownership interest	Tax residency
			%	
Osteopore Limited	Body corporate	Australia	-	Australia
Osteopore International Pte Ltd	Body corporate	Singapore	100	Singapore
Osteopore Medico Pte Ltd	Body corporate	Singapore	100	Singapore
Osteopore Australasia Pty Ltd	Body corporate	Australia	100	Australia
Osteopore (Suzhou) Medical Technology Co., Ltd	Body corporate	China	100	China
Osteopore Korea Co. Ltd	Body corporate	Korea	100	Korea

At the end of the financial year, no entity within the consolidated entity was a partner in a partnership within the consolidated entity, or a participant in a joint venture within the consolidated entity.

**Osteopore Limited and its Controlled Entities**  
**Directors' Declaration**  
**For the year ended 31 December 2024**

In accordance with a resolution of the directors of Osteopore Limited, I state that:

1. In the opinion of the directors:

- the attached financial statements and notes comply with the Corporations Act 2001, the Accounting Standards, the Corporations Regulations 2001 and other mandatory professional reporting requirements;
- the attached financial statements and notes comply with International Financial Reporting Standards as issued by the International Accounting Standards Board as described in note 1 to the financial statements;
- the attached financial statements and notes give a true and fair view of the Group's financial position as at 31 December 2024 and of its performance for the financial year ended on that date;
- there are reasonable grounds to believe that the Company will be able to pay its debts as and when they become due and payable; and
- the information disclosed in the attached consolidated entity disclosure statement is true and correct.

The Directors have been given the declarations required by section 295A of the Corporations Act 2001.

Signed in accordance with a resolution of Directors made pursuant to section 295(5)(a) of the Corporations Act 2001.

On behalf of the Directors



Mark Leong  
Executive Chairman  
7 April 2025

## Independent Auditor's Report

### To the Members of Osteopore Limited

#### Report on the audit of the financial report

##### Opinion

We have audited the financial report of Osteopore Limited (the Company) and its subsidiaries (the Group), which comprises the consolidated statement of financial position as at 31 December 2024, the consolidated statement of profit or loss and other comprehensive income, consolidated statement of changes in equity and consolidated statement of cash flows for the year then ended, and notes to the consolidated financial statements, including material accounting policy information, the consolidated entity disclosure statement and the directors' declaration.

In our opinion, the accompanying financial report of the Group is in accordance with the *Corporations Act 2001*, including:

- a giving a true and fair view of the Group's financial position as at 31 December 2024 and of its performance for the year ended on that date; and
- b complying with Australian Accounting Standards and the *Corporations Regulations 2001*.

##### Basis for opinion

We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Report* section of our report. We are independent of the Group in accordance with the auditor independence requirements of the *Corporations Act 2001* and the ethical requirements of the Accounting Professional and Ethical Standards Board's APES 110 *Code of Ethics for Professional Accountants (including Independence Standards)* (the Code) that are relevant to our audit of the financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

#### Material uncertainty related to going concern

We draw attention to Note 1 in the financial statements, which indicates that the Group incurred a net loss of \$3,352,436 during the year ended 31 December 2024, and had net operating cash outflows for the year of \$3,087,972. As stated in Note 1, these events or conditions, along with other matters as set forth in Note 1, indicate that a material uncertainty exists that may cast doubt on the Group's ability to continue as a going concern. Our opinion is not modified in respect of this matter.

**www.grantthornton.com.au**  
**ACN-130 913 594**

Grant Thornton Audit Pty Ltd ACN 130 913 594 a subsidiary or related entity of Grant Thornton Australia Limited ABN 41 127 556 389 ACN 127 556 389. 'Grant Thornton' refers to the brand under which the Grant Thornton member firms provide assurance, tax and advisory services to their clients and/or refers to one or more member firms, as the context requires. Grant Thornton Australia Limited is a member firm of Grant Thornton International Ltd (GTIL). GTIL and the member firms are not a worldwide partnership. GTIL and each member firm is a separate legal entity. Services are delivered by the member firms. GTIL does not provide services to clients. GTIL and its member firms are not agents of, and do not obligate one another and are not liable for one another's acts or omissions. In the Australian context only, the use of the term 'Grant Thornton' may refer to Grant Thornton Australia Limited ABN 41 127 556 389 ACN 127 556 389 and its Australian subsidiaries and related entities. Liability limited by a scheme approved under Professional Standards Legislation.

## Key audit matters

Key audit matters are those matters that, in our professional judgement, were of most significance in our audit of the financial report of the current period. These matters were addressed in the context of our audit of the financial report as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

In addition to the matter described in the Material uncertainty related to going concern section, we have determined the matters described below to be the key audit matters to be communicated in our report.

Key audit matter	How our audit addressed the key audit matter
<b>Revenue recognition– Note 1 and 3</b>	
<p>The Group recognised \$2,811,443 of revenue from contracts with customers for the period ended 31 December 2024, primarily from the sale of patent-protected biometric scaffolds.</p> <p>Revenue is recognised in accordance with AASB 15 <i>Revenue from Contracts with Customers</i>, at the point in time when control of the goods transfers to the customers. In certain arrangements, goods are supplied on consignment and revenue is recognised upon sale to the third-party customer by the consignee.</p> <p>Revenue recognition involves judgement in determining the timing of revenue, particularly where performance obligations and transfer of control are influenced by consignment arrangements.</p> <p>This is a key audit matter due to the judgement involved in applying AASB 15, the nature of the Group's contractual arrangements, and the significance of revenue to the financial statements.</p>	<p>Our procedures included, amongst others:</p> <ul style="list-style-type: none"><li>• Obtaining an understanding of, and evaluating, the design and implementation of internal controls relating to revenue recognition;</li><li>• Evaluating a sample of customer contracts to assess the identification of performance obligations and timing of revenue recognition under AASB 15;;</li><li>• Testing a sample of revenue transactions, including those involving consignment arrangements, to assess whether control was transferred and revenue recognised appropriately;</li><li>• Inspecting credit notes issued after balance sheet date to assess whether revenue has been recognised in the correct period; and</li></ul> <p>Assessing the adequacy of Group's revenue-related disclosures in the financial statements in accordance with AASB 15.</p>

## Information other than the financial report and auditor's report thereon

The Directors are responsible for the other information. The other information comprises the information included in the Group's annual report for the year ended 31 December 2024, but does not include the financial report and our auditor's report thereon.

Our opinion on the financial report does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial report, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial report or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

## Responsibilities of the Directors for the financial report

The Directors of the Company are responsible for the preparation of:

- a) the financial report that gives a true and fair view in accordance with Australian Accounting Standards and the Corporations Act 2001 (other than the consolidated entity disclosure statement); and
- b) the consolidated entity disclosure statement that is true and correct in accordance with the Corporations Act 2001, and



for such internal control as the directors determine is necessary to enable the preparation of:

- i) the financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error; and
- ii) the consolidated entity disclosure statement that is true and correct and is free of misstatement, whether due to fraud or error.

In preparing the financial report, the Directors are responsible for assessing the Group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Directors either intend to liquidate the Group or to cease operations, or have no realistic alternative but to do so.

### **Auditor's responsibilities for the audit of the financial report**

Our objectives are to obtain reasonable assurance about whether the financial report as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Australian Auditing Standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this financial report.

A further description of our responsibilities for the audit of the financial report is located at the Auditing and Assurance Standards Board website at: [https://www.auasb.gov.au/media/bwvjcgre/ar1\\_2024.pdf](https://www.auasb.gov.au/media/bwvjcgre/ar1_2024.pdf). This description forms part of our auditor's report.

### **Report on the remuneration report**

#### **Opinion on the remuneration report**

We have audited the Remuneration Report included in pages 10 to 18 of the Directors' report for the year ended 31 December 2024.

In our opinion, the Remuneration Report of Osteopore Limited, for the year ended 31 December 2024 complies with section 300A of the *Corporations Act 2001*.

### **Responsibilities**

The Directors of the Company are responsible for the preparation and presentation of the Remuneration Report in accordance with section 300A of the *Corporations Act 2001*. Our responsibility is to express an opinion on the Remuneration Report, based on our audit conducted in accordance with Australian Auditing Standards.

Grant Thornton

GRANT THORNTON AUDIT PTY LTD  
Chartered Accountants



J C Rubelli  
Partner – Audit & Assurance

Perth, 7 April 2025

**Osteopore Limited and its Controlled Entities**  
**ASX Additional Information**

Additional information required by the Australian Securities Exchange and not shown elsewhere in this report is as follows. The information is current at 27 March 2025.

**ORDINARY FULLY PAID SHARES**

The Company has 120,868,535 ordinary fully paid shares on issue.

**Substantial Shareholders**

The names of the substantial shareholders (who hold 5% or more of the issue capital) are listed below:

Name	Number of Shares	%
CITICORP NOMINEES PTY LIMITED	11,475,785	9.49
BNP PARIBAS NOMS PTY LTD UOBKH A/C R'MIERS	7,493,264	6.20
BNP PARIBAS NOMINEES PTY LTD <IB AU NOMS	6,123,942	5.07
<b>Total</b>	<b>25,092,991</b>	<b>20.76</b>

**Distribution of Shareholders**

	Number of Shares	Number of Holders
100,001 and Over	101,097,197	192
10,001 to 100,000	17,591,560	476
5,001 to 10,000	1,256,333	159
1,001 to 5,000	621,305	259
1 to 1,000	302,140	1,130
<b>Total</b>	<b>120,868,535</b>	<b>2,216</b>

There were 1,756 holders of ordinary shares holding less than a marketable parcel.

**Top Twenty Shareholders**

The names of the twenty largest holders of quoted shares are listed below:

Name	Number of Shares	%
CITICORP NOMINEES PTY LIMITED	11,475,785	9.49
BNP PARIBAS NOMINEES PTY LTD <UOBKH R'MIERS>	7,493,264	6.20
BNP PARIBAS NOMINEES PTY LTD <IB AU NOMS RETAILCLIENT>	6,123,942	5.07
MR KELVIN CHUA YONG WEI	3,480,919	2.88
BNP PARIBAS NOMS PTY LTD	3,464,764	2.87
MR EVAN PHILIP CLUCAS & MS LEANNE JANE WESTON <KURANGA NURSERY SUPER A/C>	3,273,864	2.71
MR MICHAEL JOHN DONNELLY & MRS KYLIE JAYNE DONNELLY <M DONNELLY SUPERFUND A/C>	3,119,207	2.58
MR ROMMEL AINZA GAN & MS SHENNIE CHUA CHUA	2,819,000	2.33
EXOSPHERE INVESTMENTS PTY LTD	2,619,067	2.17
DR RUSSELL KAY HANCOCK	2,000,000	1.65
MS FIONA ELIZABETH GREENHILL	1,923,245	1.59
ABN AMRO CLEARING SYDNEY NOMINEES PTY LTD <CUSTODIAN A/C>	1,865,213	1.54
ADVANCE OPPORTUNITIES FUND I	1,567,398	1.30

**Osteopore Limited and its Controlled Entities**  
**ASX Additional Information**

<b>Name</b>	<b>Number of Shares</b>	<b>%</b>
MR ANDREW FRASER KERR	1,540,000	1.27
TERRY MORRIS PTY LTD <MORRIS FAMILY SUPER A/C>	1,275,000	1.05
KORONEOS HOLDINGS PTY LTD	1,000,000	0.83
MR MAO CAI	907,440	0.75
MERRILL LYNCH (AUSTRALIA) NOMINEES PTY LIMITED	900,103	0.74
MS KATHLEEN HAN	894,504	0.74
MS FIONA ELIZABETH GREENHILL	835,767	0.69
<b>Total</b>	<b>58,578,482</b>	<b>48.46</b>

**QUOTED OPTIONS**

The Company has on issue 3,510,164 quoted options exercisable at \$3.375 each, expiring on 24 April 2026.

**Substantial Option Holders**

The name of the quoted option holders (who hold 5% or more of the quoted options issued) are listed below:

<b>Name</b>	<b>Number of Options</b>	<b>%</b>
MR GIANPIETRO DALTOE <SL & M DALTOE A/C>	356,757	10.16
NHT ENTERPRISES PTY LIMITED	246,108	7.01
KINCLAVEN FAMILY PTY LTD <MCKERCHER GROWTH FUND A/C>	225,000	6.41
<b>Total</b>	<b>827,865</b>	<b>23.58</b>

**Distribution of Option Holders**

	<b>Number of Holders</b>	<b>Number of Options</b>
100,001 and Over	9	1,738,111
10,001 to 100,000	47	1,372,616
5,001 to 10,000	30	222,455
1,001 to 5,000	59	132,997
1 to 1,000	170	43,985
<b>TOTAL</b>	<b>315</b>	<b>3,510,164</b>

**Top Twenty Option Holders**

The names of the twenty largest holders of quoted options are listed below:

<b>Name</b>	<b>Number of Options</b>	<b>%</b>
MR GIANPIETRO DALTOE <SL & M DALTOE A/C>	356,757	10.16
NHT ENTERPRISES PTY LIMITED	246,108	7.01
KINCLAVEN FAMILY PTY LTD <MCKERCHER GROWTH FUND A/C>	225,000	6.41
MR PATRICK JOHN MCHALE	200,000	5.70
MR KIET TUAN PHAM	190,665	5.43
DR RUSSELL KAY HANCOCK	133,334	3.80
GILSMITH SMSF PTY LTD <GILSMITH PTY LTD SF A/C>	133,334	3.80
CITICORP NOMINEES PTY LIMITED	130,394	3.71
BNP PARIBAS NOMINEES PTY LTD <UOBKH R'MIERS>	122,519	3.49
MR DAVID JOHN KELLY	100,000	2.85
MR KOUROS CYRUS ABBASZADEH <ABBASZADEH FAMILY A/C>	90,937	2.59

**Osteopore Limited and its Controlled Entities**  
**ASX Additional Information**

<b>Name</b>	<b>Number of Options</b>	<b>%</b>
HSBC CUSTODY NOMINEES (AUSTRALIA) LIMITED	79,387	2.26
SCINTILLA CAPITAL PTY LTD	66,667	1.90
DIETMAR HUTMACHER	66,667	1.90
MR JUN LIU	55,556	1.58
MR HYUNGDAE SHIN	55,000	1.57
MATTHEW BURFORD SUPER FUND PTY LTD <BURFORD SUPERFUND A/C>	46,667	1.33
MRS ANGELA JEAN RICHES	43,219	1.23
MR GEORGE COLIN SMITH	38,779	1.10
MR DWAYNE MICHAEL PINTO	34,077	0.97
FINSOL GROUP PTY LTD	33,334	0.95
MR LIAN HEO DING	32,593	0.93
<b>Total</b>	<b>2,480,994</b>	<b>70.68</b>

**UNQUOTED EQUITY SECURITIES**

<b>Type</b>	<b>Expiry</b>	<b>Exercise Price</b>	<b>Number on Issue</b>	<b>Holders</b>
Unlisted Options	02/11/2025	\$9.36	12,500	1
Unlisted Options	02/04/2026	\$0.0387	13,118,969	339
Performance Rights A	10/05/2028	\$3.75	80,001	3
Performance Rights B	10/05/2028	\$4.50	120,000	3
Performance Rights C	10/05/2028	\$5.625	140,001	3
Performance Rights D	10/05/2028	\$7.125	180,000	3
Performance Rights E	10/05/2028	\$8.25	220,002	3
Vendor Performance Rights	23/05/2028	N/A	160,000	1
Convertible Notes	N/A	N/A	40	1

**ON-MARKET BUY BACK**

There is no current on-market buy back.

**VOTING RIGHTS**

All ordinary shares carry one vote per share without restriction. Options and Performance Rights have no voting rights.

**RESTRICTED SECURITIES**

The Company does not have any restricted securities (including voluntary restricted securities).